id	sid	tid	token	lemma	pos
njb-3	1	1	nepal	nepal	PROPN
njb-3	1	2	j	j	PROPN
njb-3	1	3	biotechnol	biotechnol	PROPN
njb-3	1	4	.	.	PUNCT
njb-3	2	1	2	2	NUM
njb-3	2	2	0	0	NUM
njb-3	2	3	2	2	NUM
njb-3	2	4	1	1	NUM
njb-3	2	5	d	d	X
njb-3	2	6	e	e	X
njb-3	2	7	c	c	PROPN
njb-3	2	8	.	.	PUNCT
njb-3	3	1	9	9	NUM
njb-3	3	2	(	(	PUNCT
njb-3	3	3	2	2	NUM
njb-3	3	4	):	):	PUNCT
njb-3	3	5	29	29	NUM
njb-3	3	6	-	-	SYM
njb-3	3	7	32	32	NUM
njb-3	3	8	research	research	NOUN
njb-3	3	9	article	article	NOUN
njb-3	3	10	doi	doi	PROPN
njb-3	3	11	:	:	PUNCT
njb-3	3	12	https://www.doi.org/10.54796/njb.v9i2.41912	https://www.doi.org/10.54796/njb.v9i2.41912	PROPN
njb-3	4	1	©	©	PROPN
njb-3	4	2	njb	njb	PROPN
njb-3	4	3	,	,	PUNCT
njb-3	4	4	bsn	bsn	PROPN
njb-3	4	5	29	29	NUM
njb-3	4	6	sero	sero	NOUN
njb-3	4	7	-	-	PUNCT
njb-3	4	8	prevalance	prevalance	NOUN
njb-3	4	9	of	of	ADP
njb-3	4	10	cryptococcal	cryptococcal	ADJ
njb-3	4	11	antigenemia	antigenemia	NOUN
njb-3	4	12	in	in	ADP
njb-3	4	13	hiv	hiv	PROPN
njb-3	4	14	positive	positive	ADJ
njb-3	4	15	individual	individual	NOUN
njb-3	4	16	having	have	VERB
njb-3	4	17	cd4	cd4	PROPN
njb-3	4	18	counts	count	VERB
njb-3	4	19	<	<	X
njb-3	4	20	100	100	NUM
njb-3	4	21	cells	cell	NOUN
njb-3	4	22	/	/	SYM
njb-3	4	23	mm3	mm3	PROPN
njb-3	4	24	sundar	sundar	NOUN
njb-3	4	25	khadka	khadka	NOUN
njb-3	4	26	,	,	PUNCT
njb-3	4	27	samikshya	samikshya	PROPN
njb-3	4	28	kandel	kandel	PROPN
njb-3	4	29	,	,	PUNCT
njb-3	4	30	roshan	roshan	PROPN
njb-3	4	31	pandit	pandit	PROPN
njb-3	4	32	,	,	PUNCT
njb-3	4	33	rosham	rosham	PROPN
njb-3	4	34	manjhi	manjhi	PROPN
njb-3	4	35	,	,	PUNCT
njb-3	4	36	subhash	subhash	PROPN
njb-3	4	37	dhital	dhital	PROPN
njb-3	4	38	,	,	PUNCT
njb-3	4	39	jagat	jagat	PROPN
njb-3	4	40	bahadur	bahadur	PROPN
njb-3	4	41	baniya	baniya	PROPN
njb-3	4	42	,	,	PUNCT
njb-3	4	43	shravan	shravan	PROPN
njb-3	4	44	kumar	kumar	PROPN
njb-3	4	45	mishra	mishra	PROPN
njb-3	4	46	,	,	PUNCT
njb-3	4	47	raj	raj	PROPN
njb-3	4	48	kumar	kumar	PROPN
njb-3	4	49	mahato	mahato	PROPN
njb-3	4	50	national	national	PROPN
njb-3	4	51	public	public	PROPN
njb-3	4	52	health	health	PROPN
njb-3	4	53	laboratory	laboratory	PROPN
njb-3	4	54	(	(	PUNCT
njb-3	4	55	nphl	nphl	PROPN
njb-3	4	56	)	)	PUNCT
njb-3	4	57	,	,	PUNCT
njb-3	4	58	department	department	NOUN
njb-3	4	59	of	of	ADP
njb-3	4	60	health	health	NOUN
njb-3	4	61	services	service	NOUN
njb-3	4	62	,	,	PUNCT
njb-3	4	63	ministry	ministry	NOUN
njb-3	4	64	of	of	ADP
njb-3	4	65	health	health	PROPN
njb-3	4	66	and	and	CCONJ
njb-3	4	67	population	population	NOUN
njb-3	4	68	,	,	PUNCT
njb-3	4	69	teku	teku	NOUN
njb-3	4	70	,	,	PUNCT
njb-3	4	71	kathmandu	kathmandu	NOUN
njb-3	4	72	44	44	NUM
njb-3	4	73	-	-	SYM
njb-3	4	74	600	600	NUM
njb-3	4	75	,	,	PUNCT
njb-3	4	76	nepal	nepal	ADJ
njb-3	4	77	received	receive	VERB
njb-3	4	78	:	:	PUNCT
njb-3	4	79	5th	5th	ADJ
njb-3	4	80	nov	nov	PROPN
njb-3	4	81	2020	2020	NUM
njb-3	4	82	;	;	PUNCT
njb-3	4	83	revised	revise	VERB
njb-3	4	84	:	:	PUNCT
njb-3	4	85	21st	21st	NOUN
njb-3	4	86	sep	sep	PROPN
njb-3	4	87	2021	2021	NUM
njb-3	4	88	;	;	PUNCT
njb-3	4	89	accepted	accept	VERB
njb-3	4	90	:	:	PUNCT
njb-3	4	91	17th	17th	NOUN
njb-3	4	92	nov	nov	PROPN
njb-3	4	93	2021	2021	NUM
njb-3	4	94	;	;	PUNCT
njb-3	4	95	published	publish	VERB
njb-3	4	96	online	online	ADV
njb-3	4	97	:	:	PUNCT
njb-3	4	98	31st	31st	PROPN
njb-3	5	1	dec	dec	PROPN
njb-3	5	2	2021	2021	NUM
njb-3	5	3	abstract	abstract	ADJ
njb-3	5	4	cryptococcus	cryptococcus	PROPN
njb-3	5	5	neoformans	neoformans	PROPN
njb-3	5	6	is	be	AUX
njb-3	5	7	one	one	NUM
njb-3	5	8	of	of	ADP
njb-3	5	9	the	the	DET
njb-3	5	10	foremost	foremost	ADJ
njb-3	5	11	common	common	ADJ
njb-3	5	12	opportunistic	opportunistic	ADJ
njb-3	5	13	infectious	infectious	ADJ
njb-3	5	14	agents	agent	NOUN
njb-3	5	15	in	in	ADP
njb-3	5	16	people	people	NOUN
njb-3	5	17	living	live	VERB
njb-3	5	18	with	with	ADP
njb-3	5	19	acquired	acquire	VERB
njb-3	5	20	immuno	immuno	NOUN
njb-3	5	21	deficiency	deficiency	NOUN
njb-3	5	22	syndrome	syndrome	NOUN
njb-3	5	23	(	(	PUNCT
njb-3	5	24	aids	aids	PROPN
njb-3	5	25	)	)	PUNCT
njb-3	5	26	.	.	PUNCT
njb-3	6	1	it	it	PRON
njb-3	6	2	has	have	AUX
njb-3	6	3	been	be	AUX
njb-3	6	4	reported	report	VERB
njb-3	6	5	to	to	PART
njb-3	6	6	cause	cause	VERB
njb-3	6	7	about	about	ADV
njb-3	6	8	1	1	NUM
njb-3	6	9	million	million	NUM
njb-3	6	10	cases	case	NOUN
njb-3	6	11	of	of	ADP
njb-3	6	12	cryptococcal	cryptococcal	ADJ
njb-3	6	13	meningitis	meningitis	PROPN
njb-3	6	14	per	per	ADP
njb-3	6	15	year	year	NOUN
njb-3	6	16	among	among	ADP
njb-3	6	17	hiv	hiv	PROPN
njb-3	6	18	/	/	SYM
njb-3	6	19	aids	aids	PROPN
njb-3	6	20	and	and	CCONJ
njb-3	6	21	600,000	600,000	NUM
njb-3	6	22	deaths	death	NOUN
njb-3	6	23	annually	annually	ADV
njb-3	6	24	.	.	PUNCT
njb-3	7	1	this	this	DET
njb-3	7	2	study	study	NOUN
njb-3	7	3	was	be	AUX
njb-3	7	4	done	do	VERB
njb-3	7	5	to	to	PART
njb-3	7	6	find	find	VERB
njb-3	7	7	the	the	DET
njb-3	7	8	prevalence	prevalence	NOUN
njb-3	7	9	of	of	ADP
njb-3	7	10	cryptococcal	cryptococcal	ADJ
njb-3	7	11	antigenemia	antigenemia	NOUN
njb-3	7	12	among	among	ADP
njb-3	7	13	hiv	hiv	PROPN
njb-3	7	14	positive	positive	ADJ
njb-3	7	15	individuals	individual	NOUN
njb-3	7	16	having	have	VERB
njb-3	7	17	cd4counts	cd4count	NOUN
njb-3	7	18	<	<	X
njb-3	7	19	100	100	NUM
njb-3	7	20	cells	cell	NOUN
njb-3	7	21	/	/	SYM
njb-3	7	22	mm3	mm3	PROPN
njb-3	7	23	.	.	PUNCT
njb-3	8	1	a	a	DET
njb-3	8	2	cross	cross	ADJ
njb-3	8	3	-	-	ADJ
njb-3	8	4	sectional	sectional	ADJ
njb-3	8	5	study	study	NOUN
njb-3	8	6	was	be	AUX
njb-3	8	7	conducted	conduct	VERB
njb-3	8	8	in	in	ADP
njb-3	8	9	the	the	DET
njb-3	8	10	hiv	hiv	PROPN
njb-3	8	11	reference	reference	NOUN
njb-3	8	12	unit	unit	NOUN
njb-3	8	13	,	,	PUNCT
njb-3	8	14	national	national	ADJ
njb-3	8	15	public	public	ADJ
njb-3	8	16	health	health	PROPN
njb-3	8	17	laboratory	laboratory	NOUN
njb-3	8	18	from	from	ADP
njb-3	8	19	july	july	PROPN
njb-3	8	20	to	to	ADP
njb-3	8	21	december	december	PROPN
njb-3	8	22	2015	2015	NUM
njb-3	8	23	.	.	PUNCT
njb-3	9	1	the	the	DET
njb-3	9	2	study	study	NOUN
njb-3	9	3	comprised	comprise	VERB
njb-3	9	4	of	of	ADP
njb-3	9	5	99	99	NUM
njb-3	9	6	hiv	hiv	PROPN
njb-3	9	7	positive	positive	ADJ
njb-3	9	8	individuals	individual	NOUN
njb-3	9	9	having	have	VERB
njb-3	9	10	cd4counts	cd4count	NOUN
njb-3	9	11	<	<	X
njb-3	9	12	100	100	NUM
njb-3	9	13	cells	cell	NOUN
njb-3	9	14	/	/	SYM
njb-3	9	15	mm3	mm3	PROPN
njb-3	9	16	.	.	PUNCT
njb-3	10	1	cd4	cd4	PROPN
njb-3	10	2	t	t	PROPN
njb-3	10	3	cell	cell	NOUN
njb-3	10	4	count	count	NOUN
njb-3	10	5	was	be	AUX
njb-3	10	6	performed	perform	VERB
njb-3	10	7	by	by	ADP
njb-3	10	8	flow	flow	NOUN
njb-3	10	9	cytometry	cytometry	PROPN
njb-3	10	10	(	(	PUNCT
njb-3	10	11	bd	bd	PROPN
njb-3	10	12	biosciences	biosciences	PROPN
njb-3	10	13	,	,	PUNCT
njb-3	10	14	san	san	PROPN
njb-3	10	15	jose	jose	PROPN
njb-3	10	16	,	,	PUNCT
njb-3	10	17	ca	can	AUX
njb-3	10	18	,	,	PUNCT
njb-3	10	19	usa	usa	PROPN
njb-3	10	20	)	)	PUNCT
njb-3	10	21	and	and	CCONJ
njb-3	10	22	cryptococcal	cryptococcal	ADJ
njb-3	10	23	antigen	antigen	NOUN
njb-3	10	24	test	test	NOUN
njb-3	10	25	by	by	ADP
njb-3	10	26	latex	latex	PROPN
njb-3	10	27	agglutination	agglutination	NOUN
njb-3	10	28	assay	assay	PROPN
njb-3	10	29	.	.	PUNCT
njb-3	11	1	the	the	DET
njb-3	11	2	overall	overall	ADJ
njb-3	11	3	prevalence	prevalence	NOUN
njb-3	11	4	of	of	ADP
njb-3	11	5	cryptococcal	cryptococcal	ADJ
njb-3	11	6	antigenemia	antigenemia	NOUN
njb-3	11	7	was	be	AUX
njb-3	11	8	found	find	VERB
njb-3	11	9	to	to	PART
njb-3	11	10	be	be	AUX
njb-3	11	11	18.2	18.2	NUM
njb-3	11	12	%	%	NOUN
njb-3	11	13	.	.	PUNCT
njb-3	12	1	of	of	ADP
njb-3	12	2	the	the	DET
njb-3	12	3	total	total	ADJ
njb-3	12	4	ninety	ninety	NUM
njb-3	12	5	-	-	PUNCT
njb-3	12	6	nine	nine	NUM
njb-3	12	7	subjects	subject	NOUN
njb-3	12	8	enrolled	enrol	VERB
njb-3	12	9	in	in	ADP
njb-3	12	10	the	the	DET
njb-3	12	11	study	study	NOUN
njb-3	12	12	,	,	PUNCT
njb-3	12	13	72	72	NUM
njb-3	12	14	(	(	PUNCT
njb-3	12	15	72.8	72.8	NUM
njb-3	12	16	%	%	NOUN
njb-3	12	17	)	)	PUNCT
njb-3	12	18	were	be	AUX
njb-3	12	19	males	male	NOUN
njb-3	12	20	and	and	CCONJ
njb-3	12	21	27	27	NUM
njb-3	12	22	(	(	PUNCT
njb-3	12	23	27.2	27.2	NUM
njb-3	12	24	%	%	NOUN
njb-3	12	25	)	)	PUNCT
njb-3	12	26	were	be	AUX
njb-3	12	27	females	female	NOUN
njb-3	12	28	.	.	PUNCT
njb-3	13	1	the	the	DET
njb-3	13	2	mean	mean	ADJ
njb-3	13	3	age	age	NOUN
njb-3	13	4	of	of	ADP
njb-3	13	5	the	the	DET
njb-3	13	6	patients	patient	NOUN
njb-3	13	7	was	be	AUX
njb-3	13	8	38	38	NUM
njb-3	13	9	years	year	NOUN
njb-3	13	10	ranging	range	VERB
njb-3	13	11	from	from	ADP
njb-3	13	12	13	13	NUM
njb-3	13	13	to	to	PART
njb-3	13	14	69	69	NUM
njb-3	13	15	years	year	NOUN
njb-3	13	16	.	.	PUNCT
njb-3	14	1	higher	high	ADJ
njb-3	14	2	percentage	percentage	NOUN
njb-3	14	3	of	of	ADP
njb-3	14	4	female	female	NOUN
njb-3	14	5	(	(	PUNCT
njb-3	14	6	22.2	22.2	NUM
njb-3	14	7	%	%	NOUN
njb-3	14	8	)	)	PUNCT
njb-3	14	9	showed	show	VERB
njb-3	14	10	cryptococcal	cryptococcal	ADJ
njb-3	14	11	infection	infection	NOUN
njb-3	14	12	in	in	ADP
njb-3	14	13	our	our	PRON
njb-3	14	14	study	study	NOUN
njb-3	14	15	as	as	ADP
njb-3	14	16	compared	compare	VERB
njb-3	14	17	to	to	ADP
njb-3	14	18	male	male	NOUN
njb-3	14	19	(	(	PUNCT
njb-3	14	20	16.7	16.7	NUM
njb-3	14	21	%	%	NOUN
njb-3	14	22	)	)	PUNCT
njb-3	14	23	.	.	PUNCT
njb-3	15	1	the	the	DET
njb-3	15	2	study	study	NOUN
njb-3	15	3	concludes	conclude	VERB
njb-3	15	4	higher	high	ADJ
njb-3	15	5	prevalence	prevalence	NOUN
njb-3	15	6	of	of	ADP
njb-3	15	7	cryptococcal	cryptococcal	ADJ
njb-3	15	8	antigenemia	antigenemia	NOUN
njb-3	15	9	among	among	ADP
njb-3	15	10	hiv	hiv	PROPN
njb-3	15	11	infected	infect	VERB
njb-3	15	12	individuals	individual	NOUN
njb-3	15	13	and	and	CCONJ
njb-3	15	14	recommends	recommend	VERB
njb-3	15	15	cryptococcal	cryptococcal	ADJ
njb-3	15	16	antigen	antigen	PROPN
njb-3	15	17	screening	screen	VERB
njb-3	15	18	to	to	PART
njb-3	15	19	be	be	AUX
njb-3	15	20	made	make	VERB
njb-3	15	21	mandatory	mandatory	ADJ
njb-3	15	22	in	in	ADP
njb-3	15	23	hiv	hiv	PROPN
njb-3	15	24	positive	positive	ADJ
njb-3	15	25	patients	patient	NOUN
njb-3	15	26	having	have	VERB
njb-3	15	27	cd4	cd4	PROPN
njb-3	15	28	t	t	PROPN
njb-3	15	29	cells	cell	NOUN
njb-3	15	30	count	count	VERB
njb-3	15	31	below	below	ADP
njb-3	15	32	100/µl	100/µl	NUM
njb-3	15	33	.	.	PUNCT
njb-3	16	1	keywords	keyword	NOUN
njb-3	16	2	:	:	PUNCT
njb-3	16	3	cd4	cd4	X
njb-3	16	4	,	,	PUNCT
njb-3	16	5	crag	crag	PROPN
njb-3	16	6	,	,	PUNCT
njb-3	16	7	cryptococcosis	cryptococcosis	NOUN
njb-3	16	8	,	,	PUNCT
njb-3	16	9	hiv	hiv	PROPN
njb-3	16	10	,	,	PUNCT
njb-3	16	11	aids	aid	NOUN
njb-3	16	12	,	,	PUNCT
njb-3	16	13	lateral	lateral	ADJ
njb-3	16	14	flow	flow	NOUN
njb-3	16	15	assay	assay	NOUN
njb-3	16	16	.	.	PUNCT
njb-3	17	1	corresponding	correspond	VERB
njb-3	17	2	author	author	NOUN
njb-3	17	3	,	,	PUNCT
njb-3	17	4	email	email	NOUN
njb-3	17	5	:	:	PUNCT
njb-3	17	6	cls.sundar@gmail.com	cls.sundar@gmail.com	PROPN
njb-3	17	7	introduction	introduction	PROPN
njb-3	17	8	cryptococcus	cryptococcus	PROPN
njb-3	17	9	neoformans	neoformans	PROPN
njb-3	17	10	is	be	AUX
njb-3	17	11	one	one	NUM
njb-3	17	12	amongst	amongst	ADP
njb-3	17	13	the	the	DET
njb-3	17	14	most	most	ADV
njb-3	17	15	common	common	ADJ
njb-3	17	16	opportunistic	opportunistic	ADJ
njb-3	17	17	pathogens	pathogen	NOUN
njb-3	17	18	infecting	infect	VERB
njb-3	17	19	people	people	NOUN
njb-3	17	20	with	with	ADP
njb-3	17	21	advanced	advanced	ADJ
njb-3	17	22	human	human	ADJ
njb-3	17	23	immune	immune	ADJ
njb-3	17	24	deficiency	deficiency	NOUN
njb-3	17	25	virus	virus	NOUN
njb-3	17	26	(	(	PUNCT
njb-3	17	27	hiv	hiv	PROPN
njb-3	17	28	)	)	PUNCT
njb-3	17	29	.	.	PUNCT
njb-3	18	1	cryptococcal	cryptococcal	PROPN
njb-3	18	2	meningitis	meningitis	PROPN
njb-3	18	3	and	and	CCONJ
njb-3	18	4	cryptococcal	cryptococcal	ADJ
njb-3	18	5	pneumonia	pneumonia	NOUN
njb-3	18	6	are	be	AUX
njb-3	18	7	the	the	DET
njb-3	18	8	common	common	ADJ
njb-3	18	9	form	form	NOUN
njb-3	18	10	of	of	ADP
njb-3	18	11	cryptococcal	cryptococcal	ADJ
njb-3	18	12	infection	infection	NOUN
njb-3	18	13	in	in	ADP
njb-3	18	14	people	people	NOUN
njb-3	18	15	living	live	VERB
njb-3	18	16	with	with	ADP
njb-3	18	17	human	human	ADJ
njb-3	18	18	immune	immune	ADJ
njb-3	18	19	deficiency	deficiency	NOUN
njb-3	18	20	virus	virus	NOUN
njb-3	18	21	(	(	PUNCT
njb-3	18	22	plhiv	plhiv	PROPN
njb-3	18	23	)	)	PUNCT
njb-3	19	1	[	[	PUNCT
njb-3	19	2	1	1	NUM
njb-3	19	3	)	)	PUNCT
njb-3	19	4	.	.	PUNCT
njb-3	20	1	global	global	ADJ
njb-3	20	2	data	datum	NOUN
njb-3	20	3	estimates	estimate	NOUN
njb-3	20	4	in	in	ADP
njb-3	20	5	2013	2013	NUM
njb-3	20	6	shows	show	VERB
njb-3	20	7	that	that	SCONJ
njb-3	20	8	31.8	31.8	NUM
njb-3	20	9	million	million	NUM
njb-3	20	10	people	people	NOUN
njb-3	20	11	live	live	VERB
njb-3	20	12	with	with	ADP
njb-3	20	13	hiv	hiv	PROPN
njb-3	20	14	among	among	ADP
njb-3	20	15	which	which	PRON
njb-3	20	16	1.4	1.4	NUM
njb-3	20	17	million	million	NUM
njb-3	20	18	were	be	AUX
njb-3	20	19	reported	report	VERB
njb-3	20	20	for	for	ADP
njb-3	20	21	acquired	acquire	VERB
njb-3	20	22	immuno	immuno	NOUN
njb-3	20	23	deficiency	deficiency	NOUN
njb-3	20	24	syndrome	syndrome	NOUN
njb-3	20	25	(	(	PUNCT
njb-3	20	26	aids	aid	NOUN
njb-3	20	27	)	)	PUNCT
njb-3	20	28	related	related	ADJ
njb-3	20	29	death	death	NOUN
njb-3	20	30	[	[	PUNCT
njb-3	20	31	2	2	NUM
njb-3	20	32	]	]	PUNCT
njb-3	20	33	.	.	PUNCT
njb-3	21	1	cryptococcal	cryptococcal	PROPN
njb-3	21	2	meningitis	meningitis	PROPN
njb-3	21	3	is	be	AUX
njb-3	21	4	supposed	suppose	VERB
njb-3	21	5	to	to	PART
njb-3	21	6	cause	cause	VERB
njb-3	21	7	15	15	NUM
njb-3	21	8	%	%	NOUN
njb-3	21	9	of	of	ADP
njb-3	21	10	aids	aid	NOUN
njb-3	21	11	-	-	PUNCT
njb-3	21	12	related	relate	VERB
njb-3	21	13	mortality	mortality	NOUN
njb-3	21	14	[	[	NOUN
njb-3	21	15	2	2	NUM
njb-3	21	16	]	]	PUNCT
njb-3	21	17	.	.	PUNCT
njb-3	22	1	a	a	DET
njb-3	22	2	study	study	NOUN
njb-3	22	3	carried	carry	VERB
njb-3	22	4	out	out	ADP
njb-3	22	5	in	in	ADP
njb-3	22	6	2009	2009	NUM
njb-3	22	7	had	have	AUX
njb-3	22	8	estimated	estimate	VERB
njb-3	22	9	approximately	approximately	ADV
njb-3	22	10	1	1	NUM
njb-3	22	11	million	million	NUM
njb-3	22	12	cases	case	NOUN
njb-3	22	13	of	of	ADP
njb-3	22	14	cryptococcal	cryptococcal	ADJ
njb-3	22	15	meningitis	meningitis	PROPN
njb-3	23	1	[	[	X
njb-3	23	2	cm	cm	INTJ
njb-3	23	3	)	)	PUNCT
njb-3	23	4	with	with	ADP
njb-3	23	5	600,000	600,000	NUM
njb-3	23	6	deaths	death	NOUN
njb-3	23	7	worldwide	worldwide	ADV
njb-3	23	8	annually	annually	ADV
njb-3	23	9	[	[	X
njb-3	23	10	3	3	NUM
njb-3	23	11	]	]	X
njb-3	23	12	.	.	PUNCT
njb-3	24	1	cryptococcal	cryptococcal	PROPN
njb-3	24	2	meningitis	meningitis	PROPN
njb-3	24	3	represents	represent	VERB
njb-3	24	4	a	a	DET
njb-3	24	5	contagious	contagious	ADJ
njb-3	24	6	form	form	NOUN
njb-3	24	7	of	of	ADP
njb-3	24	8	the	the	DET
njb-3	24	9	cryptococcal	cryptococcal	ADJ
njb-3	24	10	disease	disease	NOUN
njb-3	24	11	that	that	PRON
njb-3	24	12	necessitates	necessitate	VERB
njb-3	24	13	hospitalization	hospitalization	NOUN
njb-3	24	14	and	and	CCONJ
njb-3	24	15	administration	administration	NOUN
njb-3	24	16	of	of	ADP
njb-3	24	17	drugs	drug	NOUN
njb-3	24	18	like	like	ADP
njb-3	24	19	amphotericin	amphotericin	PROPN
njb-3	24	20	b.	b.	PUNCT
njb-3	25	1	the	the	DET
njb-3	25	2	infection	infection	NOUN
njb-3	25	3	is	be	AUX
njb-3	25	4	common	common	ADJ
njb-3	25	5	mainly	mainly	ADV
njb-3	25	6	in	in	SCONJ
njb-3	25	7	immunocompromised	immunocompromise	VERB
njb-3	25	8	hiv	hiv	PROPN
njb-3	25	9	infected	infect	VERB
njb-3	25	10	individuals	individual	NOUN
njb-3	25	11	having	have	VERB
njb-3	25	12	cd4	cd4	PROPN
njb-3	25	13	t	t	PROPN
njb-3	25	14	lymphocytes	lymphocyte	NOUN
njb-3	25	15	count	count	VERB
njb-3	25	16	less	less	ADJ
njb-3	25	17	than	than	ADP
njb-3	25	18	100/µl	100/µl	NUM
njb-3	25	19	.	.	PUNCT
njb-3	26	1	the	the	DET
njb-3	26	2	infection	infection	NOUN
njb-3	26	3	can	can	AUX
njb-3	26	4	be	be	AUX
njb-3	26	5	treated	treat	VERB
njb-3	26	6	easily	easily	ADV
njb-3	26	7	if	if	SCONJ
njb-3	26	8	diagnosed	diagnose	VERB
njb-3	26	9	earlier	early	ADV
njb-3	26	10	.	.	PUNCT
njb-3	27	1	however	however	ADV
njb-3	27	2	,	,	PUNCT
njb-3	27	3	in	in	ADP
njb-3	27	4	several	several	ADJ
njb-3	27	5	cases	case	NOUN
njb-3	27	6	the	the	DET
njb-3	27	7	infection	infection	NOUN
njb-3	27	8	is	be	AUX
njb-3	27	9	asymptomatic	asymptomatic	ADJ
njb-3	27	10	and	and	CCONJ
njb-3	27	11	thus	thus	ADV
njb-3	27	12	go	go	VERB
njb-3	27	13	unnoticed	unnoticed	ADJ
njb-3	27	14	leading	lead	VERB
njb-3	27	15	to	to	ADP
njb-3	27	16	complications	complication	NOUN
njb-3	27	17	that	that	PRON
njb-3	27	18	may	may	AUX
njb-3	27	19	further	far	ADV
njb-3	27	20	lead	lead	VERB
njb-3	27	21	to	to	ADP
njb-3	27	22	death	death	NOUN
njb-3	27	23	of	of	ADP
njb-3	27	24	patients	patient	NOUN
njb-3	27	25	[	[	X
njb-3	27	26	4	4	NUM
njb-3	27	27	]	]	PUNCT
njb-3	27	28	.	.	PUNCT
njb-3	28	1	the	the	DET
njb-3	28	2	world	world	PROPN
njb-3	28	3	health	health	NOUN
njb-3	28	4	organization	organization	NOUN
njb-3	28	5	(	(	PUNCT
njb-3	28	6	who	who	PRON
njb-3	28	7	)	)	PUNCT
njb-3	28	8	guideline	guideline	NOUN
njb-3	28	9	recommends	recommend	VERB
njb-3	28	10	two	two	NUM
njb-3	28	11	strategies	strategy	NOUN
njb-3	28	12	for	for	ADP
njb-3	28	13	the	the	DET
njb-3	28	14	prevention	prevention	NOUN
njb-3	28	15	of	of	ADP
njb-3	28	16	cryptococcal	cryptococcal	ADJ
njb-3	28	17	meningitis	meningitis	PROPN
njb-3	28	18	;	;	PUNCT
njb-3	28	19	1	1	X
njb-3	28	20	)	)	PUNCT
njb-3	28	21	screening	screening	NOUN
njb-3	28	22	of	of	ADP
njb-3	28	23	patients	patient	NOUN
njb-3	28	24	with	with	ADP
njb-3	28	25	cd4	cd4	PROPN
njb-3	28	26	+	+	SYM
njb-3	28	27	t	t	NOUN
njb-3	28	28	cell	cell	NOUN
njb-3	28	29	counts	count	VERB
njb-3	28	30	below	below	ADP
njb-3	28	31	100	100	NUM
njb-3	28	32	cells	cell	NOUN
njb-3	28	33	/	/	SYM
njb-3	28	34	mm3	mm3	NOUN
njb-3	28	35	for	for	ADP
njb-3	28	36	cryptococcal	cryptococcal	ADJ
njb-3	28	37	antigen	antigen	NOUN
njb-3	28	38	(	(	PUNCT
njb-3	28	39	crag	crag	PROPN
njb-3	28	40	)	)	PUNCT
njb-3	28	41	and	and	CCONJ
njb-3	28	42	2	2	X
njb-3	28	43	)	)	PUNCT
njb-3	28	44	primary	primary	ADJ
njb-3	28	45	prophylaxis	prophylaxis	NOUN
njb-3	28	46	with	with	ADP
njb-3	28	47	fluconazole	fluconazole	NOUN
njb-3	28	48	for	for	ADP
njb-3	28	49	patients	patient	NOUN
njb-3	28	50	with	with	ADP
njb-3	28	51	cd4	cd4	PROPN
njb-3	28	52	+	+	SYM
njb-3	28	53	t	t	NOUN
njb-3	28	54	cell	cell	NOUN
njb-3	28	55	counts	count	VERB
njb-3	28	56	below	below	ADP
njb-3	28	57	100	100	NUM
njb-3	28	58	[	[	PUNCT
njb-3	28	59	5	5	NUM
njb-3	28	60	]	]	PUNCT
njb-3	28	61	.	.	PUNCT
njb-3	29	1	cryptococcal	cryptococcal	ADJ
njb-3	29	2	antigen	antigen	PROPN
njb-3	29	3	(	(	PUNCT
njb-3	29	4	crag	crag	PROPN
njb-3	29	5	)	)	PUNCT
njb-3	29	6	is	be	AUX
njb-3	29	7	a	a	DET
njb-3	29	8	biological	biological	ADJ
njb-3	29	9	marker	marker	NOUN
njb-3	29	10	of	of	ADP
njb-3	29	11	cryptococcal	cryptococcal	ADJ
njb-3	29	12	infection	infection	NOUN
njb-3	29	13	that	that	PRON
njb-3	29	14	can	can	AUX
njb-3	29	15	be	be	AUX
njb-3	29	16	detected	detect	VERB
njb-3	29	17	in	in	ADP
njb-3	29	18	serum	serum	NOUN
njb-3	29	19	of	of	ADP
njb-3	29	20	patients	patient	NOUN
njb-3	29	21	in	in	ADP
njb-3	29	22	an	an	DET
njb-3	29	23	average	average	NOUN
njb-3	29	24	of	of	ADP
njb-3	29	25	21	21	NUM
njb-3	29	26	days	day	NOUN
njb-3	29	27	(	(	PUNCT
njb-3	29	28	range	range	VERB
njb-3	29	29	5–234	5–234	NUM
njb-3	29	30	days	day	NOUN
njb-3	29	31	)	)	PUNCT
njb-3	29	32	before	before	ADP
njb-3	29	33	onset	onset	NOUN
njb-3	29	34	of	of	ADP
njb-3	29	35	symptoms	symptom	NOUN
njb-3	29	36	of	of	ADP
njb-3	29	37	meningitis	meningitis	PROPN
njb-3	30	1	[	[	PUNCT
njb-3	30	2	6	6	NUM
njb-3	30	3	]	]	PUNCT
njb-3	30	4	.	.	PUNCT
njb-3	31	1	cryptococcal	cryptococcal	ADJ
njb-3	31	2	infection	infection	NOUN
njb-3	31	3	can	can	AUX
njb-3	31	4	be	be	AUX
njb-3	31	5	identified	identify	VERB
njb-3	31	6	using	use	VERB
njb-3	31	7	several	several	ADJ
njb-3	31	8	laboratory	laboratory	NOUN
njb-3	31	9	tests	test	NOUN
njb-3	31	10	such	such	ADJ
njb-3	31	11	as	as	ADP
njb-3	31	12	latex	latex	NOUN
njb-3	31	13	agglutination	agglutination	NOUN
njb-3	31	14	tests	test	NOUN
njb-3	31	15	(	(	PUNCT
njb-3	31	16	lat	lat	PROPN
njb-3	31	17	)	)	PUNCT
njb-3	31	18	,	,	PUNCT
njb-3	31	19	enzyme	enzyme	NOUN
njb-3	31	20	immuno	immuno	NOUN
njb-3	31	21	assay	assay	PROPN
njb-3	31	22	(	(	PUNCT
njb-3	31	23	eia	eia	NOUN
njb-3	31	24	)	)	PUNCT
njb-3	31	25	,	,	PUNCT
njb-3	31	26	and	and	CCONJ
njb-3	31	27	polymerase	polymerase	NOUN
njb-3	31	28	chain	chain	NOUN
njb-3	31	29	reaction	reaction	NOUN
njb-3	31	30	(	(	PUNCT
njb-3	31	31	pcr	pcr	PROPN
njb-3	31	32	)	)	PUNCT
njb-3	31	33	;	;	PUNCT
njb-3	31	34	each	each	PRON
njb-3	31	35	having	have	VERB
njb-3	31	36	different	different	ADJ
njb-3	31	37	sensitivity	sensitivity	NOUN
njb-3	31	38	and	and	CCONJ
njb-3	31	39	specificity	specificity	NOUN
njb-3	31	40	[	[	PUNCT
njb-3	31	41	6	6	NUM
njb-3	31	42	]	]	PUNCT
njb-3	31	43	.	.	PUNCT
njb-3	32	1	however	however	ADV
njb-3	32	2	,	,	PUNCT
njb-3	32	3	cryptococcal	cryptococcal	ADJ
njb-3	32	4	antigen	antigen	NOUN
njb-3	32	5	detection	detection	NOUN
njb-3	32	6	using	use	VERB
njb-3	32	7	latex	latex	NOUN
njb-3	32	8	agglutination	agglutination	NOUN
njb-3	32	9	test	test	NOUN
njb-3	32	10	is	be	AUX
njb-3	32	11	performed	perform	VERB
njb-3	32	12	widely	widely	ADV
njb-3	32	13	for	for	ADP
njb-3	32	14	screening	screening	NOUN
njb-3	32	15	of	of	ADP
njb-3	32	16	cryptocococcal	cryptocococcal	ADJ
njb-3	32	17	infection	infection	NOUN
njb-3	32	18	as	as	SCONJ
njb-3	32	19	it	it	PRON
njb-3	32	20	is	be	AUX
njb-3	32	21	easy	easy	ADJ
njb-3	32	22	to	to	PART
njb-3	32	23	perform	perform	VERB
njb-3	32	24	and	and	CCONJ
njb-3	32	25	do	do	AUX
njb-3	32	26	not	not	PART
njb-3	32	27	require	require	VERB
njb-3	32	28	sophisticated	sophisticated	ADJ
njb-3	32	29	laboratory	laboratory	NOUN
njb-3	32	30	set	set	VERB
njb-3	32	31	up	up	ADP
njb-3	32	32	.	.	PUNCT
njb-3	33	1	timely	timely	ADJ
njb-3	33	2	identification	identification	NOUN
njb-3	33	3	of	of	ADP
njb-3	33	4	cryptococcosis	cryptococcosis	NOUN
njb-3	33	5	in	in	ADP
njb-3	33	6	plhiv	plhiv	PROPN
njb-3	33	7	in	in	ADP
njb-3	33	8	the	the	DET
njb-3	33	9	aids	aids	PROPN
njb-3	33	10	nepal	nepal	ADJ
njb-3	33	11	journal	journal	PROPN
njb-3	33	12	of	of	ADP
njb-3	33	13	biotechnology	biotechnology	NOUN
njb-3	33	14	publisher	publisher	NOUN
njb-3	33	15	:	:	PUNCT
njb-3	33	16	biotechnology	biotechnology	NOUN
njb-3	33	17	society	society	NOUN
njb-3	33	18	of	of	ADP
njb-3	33	19	nepal	nepal	PROPN
njb-3	33	20	issn	issn	PROPN
njb-3	33	21	(	(	PUNCT
njb-3	33	22	online	online	ADV
njb-3	33	23	):	):	PUNCT
njb-3	33	24	2467	2467	NUM
njb-3	33	25	-	-	SYM
njb-3	33	26	9313	9313	NUM
njb-3	33	27	journal	journal	NOUN
njb-3	33	28	homepage	homepage	NOUN
njb-3	33	29	:	:	PUNCT
njb-3	33	30	www.nepjol.info/index.php/njb	www.nepjol.info/index.php/njb	PROPN
njb-3	33	31	issn	issn	PROPN
njb-3	33	32	(	(	PUNCT
njb-3	33	33	print	print	NOUN
njb-3	33	34	):	):	PUNCT
njb-3	33	35	2091	2091	NUM
njb-3	33	36	-	-	SYM
njb-3	33	37	1130	1130	NUM
njb-3	33	38	https://orcid.org/0000-0002-5110-4446	https://orcid.org/0000-0002-5110-4446	NOUN
njb-3	34	1	mailto:cls.sundar@gmail.com	mailto:cls.sundar@gmail.com	X
njb-3	34	2	https://orcid.org/0000-0001-5170-5500	https://orcid.org/0000-0001-5170-5500	PROPN
njb-3	35	1	https://orcid.org/0000-0003-2946-1233	https://orcid.org/0000-0003-2946-1233	PROPN
njb-3	35	2	nepal	nepal	PROPN
njb-3	35	3	j	j	PROPN
njb-3	35	4	biotechnol	biotechnol	PROPN
njb-3	35	5	.	.	PUNCT
njb-3	36	1	2021	2021	NUM
njb-3	36	2	dec.9	dec.9	NOUN
njb-3	36	3	(	(	PUNCT
njb-3	36	4	2	2	NUM
njb-3	36	5	):	):	PUNCT
njb-3	36	6	29	29	NUM
njb-3	36	7	-	-	SYM
njb-3	36	8	32	32	NUM
njb-3	36	9	khadka	khadka	NOUN
njb-3	36	10	et	et	PROPN
njb-3	36	11	al	al	PROPN
njb-3	36	12	.	.	PUNCT
njb-3	37	1	©	©	PROPN
njb-3	37	2	njb	njb	PROPN
njb-3	37	3	,	,	PUNCT
njb-3	37	4	bsn	bsn	PROPN
njb-3	37	5	30	30	NUM
njb-3	37	6	stage	stage	NOUN
njb-3	37	7	prevents	prevent	VERB
njb-3	37	8	them	they	PRON
njb-3	37	9	from	from	ADP
njb-3	37	10	further	further	ADJ
njb-3	37	11	risk	risk	NOUN
njb-3	37	12	of	of	ADP
njb-3	37	13	morbidity	morbidity	NOUN
njb-3	37	14	and	and	CCONJ
njb-3	37	15	mortality	mortality	NOUN
njb-3	37	16	.	.	PUNCT
njb-3	38	1	there	there	PRON
njb-3	38	2	are	be	VERB
njb-3	38	3	different	different	ADJ
njb-3	38	4	prevalence	prevalence	NOUN
njb-3	38	5	rates	rate	NOUN
njb-3	38	6	of	of	ADP
njb-3	38	7	cryptococcal	cryptococcal	ADJ
njb-3	38	8	antigenemia	antigenemia	NOUN
njb-3	38	9	from	from	ADP
njb-3	38	10	different	different	ADJ
njb-3	38	11	parts	part	NOUN
njb-3	38	12	of	of	ADP
njb-3	38	13	the	the	DET
njb-3	38	14	world	world	NOUN
njb-3	38	15	[	[	PUNCT
njb-3	38	16	2	2	NUM
njb-3	38	17	,	,	PUNCT
njb-3	38	18	7	7	NUM
njb-3	38	19	-	-	SYM
njb-3	38	20	9	9	NUM
njb-3	38	21	]	]	PUNCT
njb-3	38	22	.	.	PUNCT
njb-3	39	1	however	however	ADV
njb-3	39	2	,	,	PUNCT
njb-3	39	3	there	there	PRON
njb-3	39	4	is	be	VERB
njb-3	39	5	no	no	DET
njb-3	39	6	such	such	ADJ
njb-3	39	7	study	study	NOUN
njb-3	39	8	from	from	ADP
njb-3	39	9	nepal	nepal	NOUN
njb-3	39	10	till	till	SCONJ
njb-3	39	11	date	date	NOUN
njb-3	39	12	to	to	ADP
njb-3	39	13	our	our	PRON
njb-3	39	14	knowledge	knowledge	NOUN
njb-3	39	15	.	.	PUNCT
njb-3	40	1	in	in	ADP
njb-3	40	2	this	this	DET
njb-3	40	3	regard	regard	NOUN
njb-3	40	4	we	we	PRON
njb-3	40	5	carried	carry	VERB
njb-3	40	6	out	out	ADP
njb-3	40	7	this	this	DET
njb-3	40	8	study	study	NOUN
njb-3	40	9	with	with	ADP
njb-3	40	10	the	the	DET
njb-3	40	11	objective	objective	NOUN
njb-3	40	12	to	to	PART
njb-3	40	13	find	find	VERB
njb-3	40	14	out	out	ADP
njb-3	40	15	the	the	DET
njb-3	40	16	prevalence	prevalence	NOUN
njb-3	40	17	of	of	ADP
njb-3	40	18	co	co	NOUN
njb-3	40	19	-	-	NOUN
njb-3	40	20	infection	infection	NOUN
njb-3	40	21	by	by	ADP
njb-3	40	22	cryptococcus	cryptococcus	PROPN
njb-3	40	23	neoformans	neoformans	PROPN
njb-3	40	24	in	in	ADP
njb-3	40	25	immunocompromised	immunocompromised	ADJ
njb-3	40	26	patients	patient	NOUN
njb-3	40	27	living	live	VERB
njb-3	40	28	with	with	ADP
njb-3	40	29	hiv	hiv	PROPN
njb-3	40	30	in	in	ADP
njb-3	40	31	nepal	nepal	ADJ
njb-3	40	32	.	.	PUNCT
njb-3	41	1	materials	material	NOUN
njb-3	41	2	and	and	CCONJ
njb-3	41	3	methods	method	NOUN
njb-3	41	4	a	a	DET
njb-3	41	5	cross	cross	ADJ
njb-3	41	6	-	-	ADJ
njb-3	41	7	sectional	sectional	ADJ
njb-3	41	8	study	study	NOUN
njb-3	41	9	was	be	AUX
njb-3	41	10	conducted	conduct	VERB
njb-3	41	11	in	in	ADP
njb-3	41	12	the	the	DET
njb-3	41	13	hiv	hiv	PROPN
njb-3	41	14	reference	reference	NOUN
njb-3	41	15	unit	unit	NOUN
njb-3	41	16	of	of	ADP
njb-3	41	17	national	national	ADJ
njb-3	41	18	public	public	PROPN
njb-3	41	19	health	health	PROPN
njb-3	41	20	laboratory	laboratory	PROPN
njb-3	41	21	(	(	PUNCT
njb-3	41	22	nphl	nphl	PROPN
njb-3	41	23	)	)	PUNCT
njb-3	41	24	,	,	PUNCT
njb-3	41	25	kathmandu	kathmandu	NOUN
njb-3	41	26	,	,	PUNCT
njb-3	41	27	nepal	nepal	ADJ
njb-3	41	28	from	from	ADP
njb-3	41	29	july	july	PROPN
njb-3	41	30	to	to	ADP
njb-3	41	31	december	december	PROPN
njb-3	41	32	2015	2015	NUM
njb-3	41	33	.	.	PUNCT
njb-3	42	1	samples	sample	NOUN
njb-3	42	2	were	be	AUX
njb-3	42	3	collected	collect	VERB
njb-3	42	4	from	from	ADP
njb-3	42	5	patients	patient	NOUN
njb-3	42	6	visiting	visit	VERB
njb-3	42	7	nphl	nphl	PROPN
njb-3	42	8	for	for	ADP
njb-3	42	9	cd4	cd4	PROPN
njb-3	42	10	t	t	PROPN
njb-3	42	11	cell	cell	NOUN
njb-3	42	12	count	count	NOUN
njb-3	42	13	.	.	PUNCT
njb-3	43	1	all	all	DET
njb-3	43	2	subjects	subject	NOUN
njb-3	43	3	enrolled	enrol	VERB
njb-3	43	4	in	in	ADP
njb-3	43	5	this	this	DET
njb-3	43	6	study	study	NOUN
njb-3	43	7	were	be	AUX
njb-3	43	8	hiv	hiv	PROPN
njb-3	43	9	positive	positive	ADJ
njb-3	43	10	patients	patient	NOUN
njb-3	43	11	having	have	VERB
njb-3	43	12	cd4	cd4	PROPN
njb-3	43	13	t	t	PROPN
njb-3	43	14	cells	cell	NOUN
njb-3	43	15	counts	count	VERB
njb-3	43	16	less	less	ADJ
njb-3	43	17	than	than	ADP
njb-3	43	18	100	100	NUM
njb-3	43	19	cells	cell	NOUN
njb-3	43	20	/	/	SYM
njb-3	43	21	mm3	mm3	PROPN
njb-3	43	22	.	.	PUNCT
njb-3	44	1	a	a	DET
njb-3	44	2	study	study	NOUN
njb-3	44	3	questionnaire	questionnaire	NOUN
njb-3	44	4	was	be	AUX
njb-3	44	5	used	use	VERB
njb-3	44	6	to	to	PART
njb-3	44	7	collect	collect	VERB
njb-3	44	8	demographic	demographic	ADJ
njb-3	44	9	data	datum	NOUN
njb-3	44	10	from	from	ADP
njb-3	44	11	each	each	DET
njb-3	44	12	patient	patient	NOUN
njb-3	44	13	.	.	PUNCT
njb-3	45	1	about	about	ADV
njb-3	45	2	3	3	NUM
njb-3	45	3	ml	ml	NOUN
njb-3	45	4	of	of	ADP
njb-3	45	5	edta	edta	PROPN
njb-3	45	6	whole	whole	ADJ
njb-3	45	7	blood	blood	NOUN
njb-3	45	8	was	be	AUX
njb-3	45	9	collected	collect	VERB
njb-3	45	10	from	from	ADP
njb-3	45	11	each	each	DET
njb-3	45	12	patient	patient	NOUN
njb-3	45	13	by	by	ADP
njb-3	45	14	trained	train	VERB
njb-3	45	15	professionals	professional	NOUN
njb-3	45	16	for	for	ADP
njb-3	45	17	the	the	DET
njb-3	45	18	purpose	purpose	NOUN
njb-3	45	19	of	of	ADP
njb-3	45	20	this	this	DET
njb-3	45	21	study	study	NOUN
njb-3	45	22	.	.	PUNCT
njb-3	46	1	the	the	DET
njb-3	46	2	whole	whole	ADJ
njb-3	46	3	blood	blood	NOUN
njb-3	46	4	sample	sample	NOUN
njb-3	46	5	was	be	AUX
njb-3	46	6	used	use	VERB
njb-3	46	7	to	to	PART
njb-3	46	8	determine	determine	VERB
njb-3	46	9	cd4	cd4	PROPN
njb-3	46	10	t	t	PROPN
njb-3	46	11	cell	cell	NOUN
njb-3	46	12	count	count	NOUN
njb-3	46	13	by	by	ADP
njb-3	46	14	flow	flow	NOUN
njb-3	46	15	cytometry	cytometry	NOUN
njb-3	46	16	using	use	VERB
njb-3	46	17	the	the	DET
njb-3	46	18	bd	bd	PROPN
njb-3	46	19	fluorescent	fluorescent	NOUN
njb-3	46	20	-	-	PUNCT
njb-3	46	21	activated	activate	VERB
njb-3	46	22	cell	cell	NOUN
njb-3	46	23	sorter	sorter	NOUN
njb-3	46	24	system	system	NOUN
njb-3	46	25	(	(	PUNCT
njb-3	46	26	bd	bd	PROPN
njb-3	46	27	biosciences	biosciences	PROPN
njb-3	46	28	,	,	PUNCT
njb-3	46	29	san	san	PROPN
njb-3	46	30	jose	jose	PROPN
njb-3	46	31	,	,	PUNCT
njb-3	46	32	ca	can	AUX
njb-3	46	33	,	,	PUNCT
njb-3	46	34	usa	usa	PROPN
njb-3	46	35	)	)	PUNCT
njb-3	46	36	as	as	ADP
njb-3	46	37	per	per	ADP
njb-3	46	38	the	the	DET
njb-3	46	39	manufacturer	manufacturer	NOUN
njb-3	46	40	’s	’s	PART
njb-3	46	41	instructions	instruction	NOUN
njb-3	46	42	.	.	PUNCT
njb-3	47	1	briefly	briefly	ADV
njb-3	47	2	,	,	PUNCT
njb-3	47	3	20	20	NUM
njb-3	47	4	μl	μl	PROPN
njb-3	47	5	of	of	ADP
njb-3	47	6	bd	bd	PROPN
njb-3	47	7	tritest	tritest	PROPN
njb-3	47	8	cd3	cd3	PROPN
njb-3	47	9	/	/	SYM
njb-3	47	10	cd4	cd4	PROPN
njb-3	47	11	/	/	SYM
njb-3	47	12	cd45	cd45	PROPN
njb-3	47	13	reagent	reagent	NOUN
njb-3	47	14	was	be	AUX
njb-3	47	15	pipetted	pipette	VERB
njb-3	47	16	into	into	ADP
njb-3	47	17	a	a	DET
njb-3	47	18	bd	bd	PROPN
njb-3	47	19	trucount	trucount	PROPN
njb-3	47	20	tube	tube	PROPN
njb-3	47	21	containing	contain	VERB
njb-3	47	22	bead	bead	NOUN
njb-3	47	23	followed	follow	VERB
njb-3	47	24	by	by	ADP
njb-3	47	25	50	50	NUM
njb-3	47	26	μl	μl	NOUN
njb-3	47	27	of	of	ADP
njb-3	47	28	well	well	ADV
njb-3	47	29	-	-	PUNCT
njb-3	47	30	mixed	mix	VERB
njb-3	47	31	anticoagulated	anticoagulate	VERB
njb-3	47	32	whole	whole	ADJ
njb-3	47	33	blood	blood	NOUN
njb-3	47	34	which	which	PRON
njb-3	47	35	was	be	AUX
njb-3	47	36	then	then	ADV
njb-3	47	37	vortexed	vortexe	VERB
njb-3	47	38	and	and	CCONJ
njb-3	47	39	incubated	incubate	VERB
njb-3	47	40	in	in	ADP
njb-3	47	41	dark	dark	NOUN
njb-3	47	42	at	at	ADP
njb-3	47	43	room	room	NOUN
njb-3	47	44	temperature	temperature	NOUN
njb-3	47	45	for	for	ADP
njb-3	47	46	15	15	NUM
njb-3	47	47	minutes	minute	NOUN
njb-3	47	48	for	for	ADP
njb-3	47	49	staining	staining	NOUN
njb-3	47	50	of	of	ADP
njb-3	47	51	the	the	DET
njb-3	47	52	cells	cell	NOUN
njb-3	47	53	.	.	PUNCT
njb-3	48	1	following	follow	VERB
njb-3	48	2	staining	stain	VERB
njb-3	48	3	cells	cell	NOUN
njb-3	48	4	were	be	AUX
njb-3	48	5	lysed	lyse	VERB
njb-3	48	6	using	use	VERB
njb-3	48	7	bd	bd	PROPN
njb-3	48	8	facs	facs	PROPN
njb-3	48	9	lysing	lysing	NOUN
njb-3	48	10	solution	solution	NOUN
njb-3	48	11	and	and	CCONJ
njb-3	48	12	run	run	VERB
njb-3	48	13	in	in	ADP
njb-3	48	14	the	the	DET
njb-3	48	15	flow	flow	NOUN
njb-3	48	16	cytometer	cytometer	NOUN
njb-3	48	17	to	to	PART
njb-3	48	18	obtain	obtain	VERB
njb-3	48	19	absolute	absolute	ADJ
njb-3	48	20	count	count	NOUN
njb-3	48	21	.	.	PUNCT
njb-3	49	1	for	for	SCONJ
njb-3	49	2	the	the	DET
njb-3	49	3	purpose	purpose	NOUN
njb-3	49	4	of	of	ADP
njb-3	49	5	cryptococcal	cryptococcal	ADJ
njb-3	49	6	antigen	antigen	PROPN
njb-3	49	7	testing	testing	NOUN
njb-3	49	8	plasma	plasma	NOUN
njb-3	49	9	sample	sample	NOUN
njb-3	49	10	was	be	AUX
njb-3	49	11	separated	separate	VERB
njb-3	49	12	from	from	ADP
njb-3	49	13	edta	edta	PROPN
njb-3	49	14	whole	whole	ADJ
njb-3	49	15	blood	blood	NOUN
njb-3	49	16	,	,	PUNCT
njb-3	49	17	which	which	PRON
njb-3	49	18	was	be	AUX
njb-3	49	19	then	then	ADV
njb-3	49	20	used	use	VERB
njb-3	49	21	for	for	ADP
njb-3	49	22	antigen	antigen	NOUN
njb-3	49	23	detection	detection	NOUN
njb-3	49	24	using	use	VERB
njb-3	49	25	cryptococcal	cryptococcal	ADJ
njb-3	49	26	latex	latex	NOUN
njb-3	49	27	agglutination	agglutination	NOUN
njb-3	49	28	test	test	NOUN
njb-3	49	29	(	(	PUNCT
njb-3	49	30	immuno	immuno	PROPN
njb-3	49	31	mycologics	mycologics	PROPN
njb-3	49	32	inc	inc	PROPN
njb-3	49	33	,	,	PUNCT
njb-3	49	34	usa	usa	PROPN
njb-3	49	35	)	)	PUNCT
njb-3	49	36	.	.	PUNCT
njb-3	50	1	the	the	DET
njb-3	50	2	test	test	NOUN
njb-3	50	3	kit	kit	NOUN
njb-3	50	4	employed	employ	VERB
njb-3	50	5	is	be	AUX
njb-3	50	6	based	base	VERB
njb-3	50	7	on	on	ADP
njb-3	50	8	antigenantibody	antigenantibody	ADJ
njb-3	50	9	agglutination	agglutination	NOUN
njb-3	50	10	reaction	reaction	NOUN
njb-3	50	11	that	that	PRON
njb-3	50	12	detects	detect	VERB
njb-3	50	13	capsular	capsular	ADJ
njb-3	50	14	polysaccharide	polysaccharide	ADJ
njb-3	50	15	antigen	antigen	NOUN
njb-3	50	16	of	of	ADP
njb-3	50	17	c.	c.	PROPN
njb-3	50	18	neoformans	neoformans	PROPN
njb-3	50	19	.	.	PUNCT
njb-3	51	1	the	the	DET
njb-3	51	2	test	test	NOUN
njb-3	51	3	kit	kit	NOUN
njb-3	51	4	is	be	AUX
njb-3	51	5	believed	believe	VERB
njb-3	51	6	to	to	PART
njb-3	51	7	have	have	VERB
njb-3	51	8	higher	high	ADJ
njb-3	51	9	specificity	specificity	NOUN
njb-3	51	10	and	and	CCONJ
njb-3	51	11	greater	great	ADJ
njb-3	51	12	than	than	ADP
njb-3	51	13	95	95	NUM
njb-3	51	14	%	%	NOUN
njb-3	51	15	sensitivity	sensitivity	NOUN
njb-3	51	16	.	.	PUNCT
njb-3	52	1	the	the	DET
njb-3	52	2	assay	assay	NOUN
njb-3	52	3	procedure	procedure	NOUN
njb-3	52	4	involves	involve	VERB
njb-3	52	5	5	5	NUM
njb-3	52	6	-	-	PUNCT
njb-3	52	7	easy	easy	ADJ
njb-3	52	8	steps	step	NOUN
njb-3	52	9	with	with	ADP
njb-3	52	10	no	no	DET
njb-3	52	11	specimen	speciman	NOUN
njb-3	52	12	pretreatment	pretreatment	NOUN
njb-3	52	13	.	.	PUNCT
njb-3	53	1	for	for	ADP
njb-3	53	2	test	test	NOUN
njb-3	53	3	,	,	PUNCT
njb-3	53	4	at	at	ADP
njb-3	53	5	first	first	ADV
njb-3	53	6	a	a	DET
njb-3	53	7	drop	drop	NOUN
njb-3	53	8	of	of	ADP
njb-3	53	9	lateral	lateral	ADJ
njb-3	53	10	flow	flow	NOUN
njb-3	53	11	assay	assay	PROPN
njb-3	53	12	(	(	PUNCT
njb-3	53	13	lfa	lfa	PROPN
njb-3	53	14	)	)	PUNCT
njb-3	53	15	specimen	speciman	NOUN
njb-3	53	16	diluent	diluent	NOUN
njb-3	53	17	was	be	AUX
njb-3	53	18	added	add	VERB
njb-3	53	19	to	to	ADP
njb-3	53	20	a	a	DET
njb-3	53	21	disposable	disposable	ADJ
njb-3	53	22	test	test	NOUN
njb-3	53	23	tube	tube	NOUN
njb-3	53	24	.	.	PUNCT
njb-3	54	1	in	in	ADP
njb-3	54	2	the	the	DET
njb-3	54	3	second	second	ADJ
njb-3	54	4	step	step	NOUN
njb-3	54	5	,	,	PUNCT
njb-3	54	6	40	40	NUM
njb-3	54	7	µl	µl	NOUN
njb-3	54	8	of	of	ADP
njb-3	54	9	the	the	DET
njb-3	54	10	specimen	speciman	NOUN
njb-3	54	11	was	be	AUX
njb-3	54	12	added	add	VERB
njb-3	54	13	to	to	ADP
njb-3	54	14	the	the	DET
njb-3	54	15	tube	tube	NOUN
njb-3	54	16	and	and	CCONJ
njb-3	54	17	mixed	mixed	ADJ
njb-3	54	18	.	.	PUNCT
njb-3	55	1	afterward	afterward	ADV
njb-3	55	2	,	,	PUNCT
njb-3	55	3	a	a	DET
njb-3	55	4	crag	crag	PROPN
njb-3	55	5	lfa	lfa	PROPN
njb-3	55	6	test	test	PROPN
njb-3	55	7	strip	strip	PROPN
njb-3	55	8	was	be	AUX
njb-3	55	9	inserted	insert	VERB
njb-3	55	10	into	into	ADP
njb-3	55	11	the	the	DET
njb-3	55	12	specimen	speciman	NOUN
njb-3	55	13	and	and	CCONJ
njb-3	55	14	read	read	VERB
njb-3	55	15	at	at	ADP
njb-3	55	16	10	10	NUM
njb-3	55	17	min	min	NOUN
njb-3	55	18	.	.	PUNCT
njb-3	56	1	the	the	DET
njb-3	56	2	validity	validity	NOUN
njb-3	56	3	of	of	ADP
njb-3	56	4	the	the	DET
njb-3	56	5	test	test	NOUN
njb-3	56	6	was	be	AUX
njb-3	56	7	indicated	indicate	VERB
njb-3	56	8	by	by	ADP
njb-3	56	9	a	a	DET
njb-3	56	10	single	single	ADJ
njb-3	56	11	control	control	NOUN
njb-3	56	12	line	line	NOUN
njb-3	56	13	and	and	CCONJ
njb-3	56	14	the	the	DET
njb-3	56	15	presence	presence	NOUN
njb-3	56	16	of	of	ADP
njb-3	56	17	line	line	NOUN
njb-3	56	18	in	in	ADP
njb-3	56	19	test	test	NOUN
njb-3	56	20	region	region	NOUN
njb-3	56	21	indicated	indicate	VERB
njb-3	56	22	a	a	DET
njb-3	56	23	valid	valid	ADJ
njb-3	56	24	positive	positive	ADJ
njb-3	56	25	test	test	NOUN
njb-3	56	26	[	[	PUNCT
njb-3	56	27	10	10	NUM
njb-3	56	28	]	]	X
njb-3	56	29	.	.	PUNCT
njb-3	56	30	informed	informed	ADJ
njb-3	56	31	consent	consent	NOUN
njb-3	56	32	was	be	AUX
njb-3	56	33	from	from	ADP
njb-3	56	34	each	each	DET
njb-3	56	35	patient	patient	NOUN
njb-3	56	36	enrolled	enrol	VERB
njb-3	56	37	in	in	ADP
njb-3	56	38	this	this	DET
njb-3	56	39	study	study	NOUN
njb-3	56	40	after	after	ADP
njb-3	56	41	explaining	explain	VERB
njb-3	56	42	them	they	PRON
njb-3	56	43	with	with	ADP
njb-3	56	44	the	the	DET
njb-3	56	45	objective	objective	NOUN
njb-3	56	46	and	and	CCONJ
njb-3	56	47	outcome	outcome	NOUN
njb-3	56	48	of	of	ADP
njb-3	56	49	this	this	DET
njb-3	56	50	study	study	NOUN
njb-3	56	51	.	.	PUNCT
njb-3	57	1	ethical	ethical	ADJ
njb-3	57	2	approval	approval	NOUN
njb-3	57	3	was	be	AUX
njb-3	57	4	taken	take	VERB
njb-3	57	5	from	from	ADP
njb-3	57	6	nepal	nepal	ADJ
njb-3	57	7	health	health	NOUN
njb-3	57	8	research	research	PROPN
njb-3	57	9	council	council	NOUN
njb-3	57	10	(	(	PUNCT
njb-3	57	11	ref	ref	VERB
njb-3	57	12	no	no	NOUN
njb-3	57	13	.	.	NOUN
njb-3	57	14	892	892	NUM
njb-3	57	15	)	)	PUNCT
njb-3	57	16	before	before	ADP
njb-3	57	17	carrying	carry	VERB
njb-3	57	18	out	out	ADP
njb-3	57	19	this	this	DET
njb-3	57	20	study	study	NOUN
njb-3	57	21	.	.	PUNCT
njb-3	58	1	results	result	VERB
njb-3	58	2	a	a	DET
njb-3	58	3	total	total	NOUN
njb-3	58	4	of	of	ADP
njb-3	58	5	ninety	ninety	NUM
njb-3	58	6	-	-	PUNCT
njb-3	58	7	nine	nine	NUM
njb-3	58	8	hiv	hiv	PROPN
njb-3	58	9	positive	positive	ADJ
njb-3	58	10	patients	patient	NOUN
njb-3	58	11	were	be	AUX
njb-3	58	12	enrolled	enrol	VERB
njb-3	58	13	in	in	ADP
njb-3	58	14	the	the	DET
njb-3	58	15	study	study	NOUN
njb-3	58	16	during	during	ADP
njb-3	58	17	the	the	DET
njb-3	58	18	period	period	NOUN
njb-3	58	19	of	of	ADP
njb-3	58	20	six	six	NUM
njb-3	58	21	months	month	NOUN
njb-3	58	22	.	.	PUNCT
njb-3	59	1	the	the	DET
njb-3	59	2	study	study	NOUN
njb-3	59	3	comprised	comprise	VERB
njb-3	59	4	72	72	NUM
njb-3	59	5	males	male	NOUN
njb-3	59	6	and	and	CCONJ
njb-3	59	7	27	27	NUM
njb-3	59	8	females	female	NOUN
njb-3	59	9	which	which	PRON
njb-3	59	10	were	be	AUX
njb-3	59	11	72.8	72.8	NUM
njb-3	59	12	%	%	NOUN
njb-3	59	13	and	and	CCONJ
njb-3	59	14	27.2	27.2	NUM
njb-3	59	15	%	%	NOUN
njb-3	59	16	of	of	ADP
njb-3	59	17	the	the	DET
njb-3	59	18	total	total	NOUN
njb-3	59	19	,	,	PUNCT
njb-3	59	20	respectively	respectively	ADV
njb-3	59	21	.	.	PUNCT
njb-3	60	1	the	the	DET
njb-3	60	2	ratio	ratio	NOUN
njb-3	60	3	of	of	ADP
njb-3	60	4	male	male	NOUN
njb-3	60	5	to	to	ADP
njb-3	60	6	female	female	ADJ
njb-3	60	7	patients	patient	NOUN
njb-3	60	8	was	be	AUX
njb-3	60	9	8:3	8:3	NUM
njb-3	60	10	.	.	PUNCT
njb-3	61	1	the	the	DET
njb-3	61	2	minimum	minimum	ADJ
njb-3	61	3	and	and	CCONJ
njb-3	61	4	maximum	maximum	ADJ
njb-3	61	5	age	age	NOUN
njb-3	61	6	of	of	ADP
njb-3	61	7	study	study	NOUN
njb-3	61	8	population	population	NOUN
njb-3	61	9	was	be	AUX
njb-3	61	10	13	13	NUM
njb-3	61	11	years	year	NOUN
njb-3	61	12	and	and	CCONJ
njb-3	61	13	69	69	NUM
njb-3	61	14	years	year	NOUN
njb-3	61	15	,	,	PUNCT
njb-3	61	16	respectively	respectively	ADV
njb-3	61	17	with	with	ADP
njb-3	61	18	the	the	DET
njb-3	61	19	mean	mean	ADJ
njb-3	61	20	age	age	NOUN
njb-3	61	21	of	of	ADP
njb-3	61	22	38	38	NUM
njb-3	61	23	years	year	NOUN
njb-3	61	24	.	.	PUNCT
njb-3	62	1	the	the	DET
njb-3	62	2	mean	mean	NOUN
njb-3	62	3	cd4	cd4	PROPN
njb-3	62	4	t	t	PROPN
njb-3	62	5	cell	cell	NOUN
njb-3	62	6	count	count	NOUN
njb-3	62	7	was	be	AUX
njb-3	62	8	60.4	60.4	NUM
njb-3	62	9	that	that	PRON
njb-3	62	10	range	range	VERB
njb-3	62	11	from	from	ADP
njb-3	62	12	2	2	NUM
njb-3	62	13	to	to	PART
njb-3	62	14	98	98	NUM
njb-3	62	15	cells	cell	NOUN
njb-3	62	16	/	/	SYM
njb-3	62	17	mm3	mm3	PROPN
njb-3	62	18	.	.	X
njb-3	62	19	of	of	ADP
njb-3	62	20	the	the	DET
njb-3	62	21	total	total	ADJ
njb-3	62	22	patients	patient	NOUN
njb-3	62	23	enrolled	enrol	VERB
njb-3	62	24	in	in	ADP
njb-3	62	25	the	the	DET
njb-3	62	26	study	study	NOUN
njb-3	62	27	,	,	PUNCT
njb-3	62	28	18	18	NUM
njb-3	62	29	(	(	PUNCT
njb-3	62	30	18.2	18.2	NUM
njb-3	62	31	%	%	NOUN
njb-3	62	32	)	)	PUNCT
njb-3	62	33	were	be	AUX
njb-3	62	34	found	find	VERB
njb-3	62	35	positive	positive	ADJ
njb-3	62	36	for	for	ADP
njb-3	62	37	cryptococcal	cryptococcal	ADJ
njb-3	62	38	antigen	antigen	PROPN
njb-3	62	39	.	.	PUNCT
njb-3	63	1	the	the	DET
njb-3	63	2	positive	positive	ADJ
njb-3	63	3	to	to	ADP
njb-3	63	4	negative	negative	ADJ
njb-3	63	5	ratio	ratio	NOUN
njb-3	63	6	for	for	ADP
njb-3	63	7	cryptococcal	cryptococcal	ADJ
njb-3	63	8	antigen	antigen	PROPN
njb-3	63	9	was	be	AUX
njb-3	63	10	observed	observe	VERB
njb-3	63	11	to	to	PART
njb-3	63	12	be	be	AUX
njb-3	63	13	2:11	2:11	NUM
njb-3	63	14	.	.	PUNCT
njb-3	64	1	the	the	DET
njb-3	64	2	prevalence	prevalence	NOUN
njb-3	64	3	rate	rate	NOUN
njb-3	64	4	of	of	ADP
njb-3	64	5	cryptococcal	cryptococcal	ADJ
njb-3	64	6	antigen	antigen	NOUN
njb-3	64	7	among	among	ADP
njb-3	64	8	male	male	ADJ
njb-3	64	9	patients	patient	NOUN
njb-3	64	10	was	be	AUX
njb-3	64	11	found	find	VERB
njb-3	64	12	to	to	PART
njb-3	64	13	be	be	AUX
njb-3	64	14	16.7	16.7	NUM
njb-3	64	15	%	%	NOUN
njb-3	64	16	while	while	SCONJ
njb-3	64	17	that	that	SCONJ
njb-3	64	18	for	for	ADP
njb-3	64	19	female	female	ADJ
njb-3	64	20	patients	patient	NOUN
njb-3	64	21	was	be	AUX
njb-3	64	22	found	find	VERB
njb-3	64	23	to	to	PART
njb-3	64	24	be	be	AUX
njb-3	64	25	22.2	22.2	NUM
njb-3	64	26	%	%	NOUN
njb-3	64	27	.	.	PUNCT
njb-3	65	1	in	in	ADP
njb-3	65	2	total	total	ADJ
njb-3	65	3	,	,	PUNCT
njb-3	65	4	the	the	DET
njb-3	65	5	prevalence	prevalence	NOUN
njb-3	65	6	rate	rate	NOUN
njb-3	65	7	was	be	AUX
njb-3	65	8	18.2	18.2	NUM
njb-3	65	9	%	%	NOUN
njb-3	65	10	.	.	PUNCT
njb-3	66	1	the	the	DET
njb-3	66	2	prevalence	prevalence	NOUN
njb-3	66	3	rate	rate	NOUN
njb-3	66	4	was	be	AUX
njb-3	66	5	observed	observe	VERB
njb-3	66	6	higher	higher	ADV
njb-3	66	7	among	among	ADP
njb-3	66	8	female	female	ADJ
njb-3	66	9	patients	patient	NOUN
njb-3	66	10	as	as	SCONJ
njb-3	66	11	compared	compare	VERB
njb-3	66	12	to	to	ADP
njb-3	66	13	male	male	ADJ
njb-3	66	14	patients	patient	NOUN
njb-3	66	15	table	table	NOUN
njb-3	66	16	1	1	NUM
njb-3	66	17	.	.	PUNCT
njb-3	66	18	table	table	NOUN
njb-3	66	19	1	1	NUM
njb-3	66	20	.	.	PUNCT
njb-3	67	1	prevalence	prevalence	NOUN
njb-3	67	2	of	of	ADP
njb-3	67	3	cryptococcal	cryptococcal	ADJ
njb-3	67	4	antigen	antigen	NOUN
njb-3	67	5	among	among	ADP
njb-3	67	6	hiv	hiv	PROPN
njb-3	67	7	patients	patient	NOUN
njb-3	67	8	(	(	PUNCT
njb-3	67	9	n=99	n=99	PROPN
njb-3	67	10	)	)	PUNCT
njb-3	67	11	sex	sex	NOUN
njb-3	67	12	crag	crag	PROPN
njb-3	67	13	positive	positive	PROPN
njb-3	67	14	crag	crag	PROPN
njb-3	67	15	negative	negative	ADJ
njb-3	67	16	total	total	ADJ
njb-3	67	17	male	male	NOUN
njb-3	67	18	12	12	NUM
njb-3	67	19	(	(	PUNCT
njb-3	67	20	16.7	16.7	NUM
njb-3	67	21	%	%	NOUN
njb-3	67	22	)	)	PUNCT
njb-3	67	23	60	60	NUM
njb-3	67	24	(	(	PUNCT
njb-3	67	25	83.3	83.3	NUM
njb-3	67	26	%	%	NOUN
njb-3	67	27	)	)	PUNCT
njb-3	67	28	72	72	NUM
njb-3	67	29	(	(	PUNCT
njb-3	67	30	100	100	NUM
njb-3	67	31	%	%	NOUN
njb-3	67	32	)	)	PUNCT
njb-3	67	33	female	female	ADJ
njb-3	67	34	6	6	NUM
njb-3	67	35	(	(	PUNCT
njb-3	67	36	22.2	22.2	NUM
njb-3	67	37	%	%	NOUN
njb-3	67	38	)	)	PUNCT
njb-3	67	39	21	21	NUM
njb-3	67	40	(	(	PUNCT
njb-3	67	41	77.8	77.8	NUM
njb-3	67	42	%	%	NOUN
njb-3	67	43	)	)	PUNCT
njb-3	67	44	27	27	NUM
njb-3	67	45	(	(	PUNCT
njb-3	67	46	100	100	NUM
njb-3	67	47	%	%	NOUN
njb-3	67	48	)	)	PUNCT
njb-3	67	49	total	total	ADJ
njb-3	67	50	18	18	NUM
njb-3	67	51	(	(	PUNCT
njb-3	67	52	18.2	18.2	NUM
njb-3	67	53	%	%	NOUN
njb-3	67	54	)	)	PUNCT
njb-3	67	55	81	81	NUM
njb-3	67	56	(	(	PUNCT
njb-3	67	57	81.8	81.8	NUM
njb-3	67	58	%	%	NOUN
njb-3	67	59	)	)	PUNCT
njb-3	67	60	99	99	NUM
njb-3	67	61	(	(	PUNCT
njb-3	67	62	100	100	NUM
njb-3	67	63	%	%	NOUN
njb-3	67	64	)	)	PUNCT
njb-3	67	65	discussion	discussion	NOUN
njb-3	67	66	this	this	DET
njb-3	67	67	study	study	NOUN
njb-3	67	68	highlights	highlight	VERB
njb-3	67	69	the	the	DET
njb-3	67	70	sero	sero	NOUN
njb-3	67	71	-	-	PUNCT
njb-3	67	72	prevalence	prevalence	NOUN
njb-3	67	73	of	of	ADP
njb-3	67	74	cryptococcal	cryptococcal	ADJ
njb-3	67	75	antigen	antigen	NOUN
njb-3	67	76	in	in	ADP
njb-3	67	77	hiv	hiv	PROPN
njb-3	67	78	positive	positive	ADJ
njb-3	67	79	individuals	individual	NOUN
njb-3	67	80	having	have	VERB
njb-3	67	81	cd4	cd4	PROPN
njb-3	67	82	counts	count	NOUN
njb-3	67	83	less	less	ADJ
njb-3	67	84	than	than	ADP
njb-3	67	85	100	100	NUM
njb-3	67	86	cells	cell	NOUN
njb-3	67	87	/	/	SYM
njb-3	67	88	mm3	mm3	PROPN
njb-3	67	89	.	.	PUNCT
njb-3	68	1	hiv	hiv	PROPN
njb-3	68	2	positive	positive	ADJ
njb-3	68	3	patients	patient	NOUN
njb-3	68	4	having	have	VERB
njb-3	68	5	cd4	cd4	NOUN
njb-3	68	6	count	count	VERB
njb-3	68	7	<	<	X
njb-3	68	8	100	100	NUM
njb-3	68	9	cells	cell	NOUN
njb-3	68	10	/	/	SYM
njb-3	68	11	mm3	mm3	NOUN
njb-3	68	12	is	be	AUX
njb-3	68	13	referred	refer	VERB
njb-3	68	14	to	to	PART
njb-3	68	15	be	be	AUX
njb-3	68	16	in	in	ADP
njb-3	68	17	the	the	DET
njb-3	68	18	aids	aids	PROPN
njb-3	68	19	stage	stage	NOUN
njb-3	68	20	.	.	PUNCT
njb-3	69	1	these	these	DET
njb-3	69	2	patients	patient	NOUN
njb-3	69	3	are	be	AUX
njb-3	69	4	in	in	ADP
njb-3	69	5	immunocompromised	immunocompromised	ADJ
njb-3	69	6	state	state	NOUN
njb-3	69	7	and	and	CCONJ
njb-3	69	8	are	be	AUX
njb-3	69	9	at	at	ADP
njb-3	69	10	higher	high	ADJ
njb-3	69	11	risk	risk	NOUN
njb-3	69	12	of	of	ADP
njb-3	69	13	opportunistic	opportunistic	ADJ
njb-3	69	14	infection	infection	NOUN
njb-3	69	15	.	.	PUNCT
njb-3	70	1	cryptococcus	cryptococcus	PROPN
njb-3	70	2	neoformans	neoformans	PROPN
njb-3	70	3	is	be	AUX
njb-3	70	4	a	a	DET
njb-3	70	5	fungus	fungus	NOUN
njb-3	70	6	widely	widely	ADV
njb-3	70	7	present	present	ADJ
njb-3	70	8	in	in	ADP
njb-3	70	9	the	the	DET
njb-3	70	10	environment	environment	NOUN
njb-3	70	11	and	and	CCONJ
njb-3	70	12	are	be	AUX
njb-3	70	13	able	able	ADJ
njb-3	70	14	to	to	PART
njb-3	70	15	infect	infect	VERB
njb-3	70	16	immunocompromised	immunocompromise	VERB
njb-3	70	17	host	host	NOUN
njb-3	70	18	.	.	PUNCT
njb-3	71	1	thus	thus	ADV
njb-3	71	2	,	,	PUNCT
njb-3	71	3	hiv	hiv	PROPN
njb-3	71	4	infected	infect	VERB
njb-3	71	5	individuals	individual	NOUN
njb-3	71	6	in	in	ADP
njb-3	71	7	aids	aids	PROPN
njb-3	71	8	stage	stage	NOUN
njb-3	71	9	are	be	AUX
njb-3	71	10	highly	highly	ADV
njb-3	71	11	susceptible	susceptible	ADJ
njb-3	71	12	for	for	ADP
njb-3	71	13	opportunistic	opportunistic	ADJ
njb-3	71	14	infection	infection	NOUN
njb-3	71	15	by	by	ADP
njb-3	71	16	several	several	ADJ
njb-3	71	17	other	other	ADJ
njb-3	71	18	agents	agent	NOUN
njb-3	71	19	beside	beside	ADP
njb-3	71	20	c.	c.	PROPN
njb-3	71	21	neoformans	neoformans	PROPN
njb-3	71	22	.	.	PUNCT
njb-3	72	1	in	in	ADP
njb-3	72	2	this	this	DET
njb-3	72	3	study	study	NOUN
njb-3	72	4	,	,	PUNCT
njb-3	72	5	we	we	PRON
njb-3	72	6	have	have	AUX
njb-3	72	7	estimated	estimate	VERB
njb-3	72	8	the	the	DET
njb-3	72	9	prevalence	prevalence	NOUN
njb-3	72	10	rate	rate	NOUN
njb-3	72	11	of	of	ADP
njb-3	72	12	opportunistic	opportunistic	ADJ
njb-3	72	13	infection	infection	NOUN
njb-3	72	14	by	by	ADP
njb-3	72	15	c.	c.	PROPN
njb-3	72	16	neoformans	neoformans	PROPN
njb-3	72	17	in	in	ADP
njb-3	72	18	immunocompromised	immunocompromise	VERB
njb-3	72	19	hiv	hiv	PROPN
njb-3	72	20	positive	positive	ADJ
njb-3	72	21	individuals	individual	NOUN
njb-3	72	22	.	.	PUNCT
njb-3	73	1	the	the	DET
njb-3	73	2	prevalence	prevalence	NOUN
njb-3	73	3	of	of	ADP
njb-3	73	4	cryptococcosis	cryptococcosis	NOUN
njb-3	73	5	was	be	AUX
njb-3	73	6	18.2	18.2	NUM
njb-3	73	7	%	%	NOUN
njb-3	73	8	among	among	ADP
njb-3	73	9	99	99	NUM
njb-3	73	10	hiv	hiv	PROPN
njb-3	73	11	positive	positive	ADJ
njb-3	73	12	patients	patient	NOUN
njb-3	73	13	having	have	VERB
njb-3	73	14	cd4	cd4	NOUN
njb-3	73	15	count	count	VERB
njb-3	73	16	<	<	X
njb-3	73	17	100	100	NUM
njb-3	73	18	cells	cell	NOUN
njb-3	73	19	/	/	SYM
njb-3	73	20	mm3	mm3	NOUN
njb-3	73	21	in	in	ADP
njb-3	73	22	this	this	DET
njb-3	73	23	study	study	NOUN
njb-3	73	24	,	,	PUNCT
njb-3	73	25	which	which	PRON
njb-3	73	26	shows	show	VERB
njb-3	73	27	that	that	SCONJ
njb-3	73	28	a	a	DET
njb-3	73	29	significant	significant	ADJ
njb-3	73	30	proportion	proportion	NOUN
njb-3	73	31	of	of	ADP
njb-3	73	32	plhiv	plhiv	PROPN
njb-3	73	33	has	have	VERB
njb-3	73	34	cryptococcus	cryptococcus	PROPN
njb-3	73	35	infection	infection	NOUN
njb-3	73	36	in	in	ADP
njb-3	73	37	nepal	nepal	NOUN
njb-3	73	38	.	.	PUNCT
njb-3	74	1	this	this	DET
njb-3	74	2	finding	finding	NOUN
njb-3	74	3	is	be	AUX
njb-3	74	4	comparable	comparable	ADJ
njb-3	74	5	to	to	ADP
njb-3	74	6	a	a	DET
njb-3	74	7	study	study	NOUN
njb-3	74	8	by	by	ADP
njb-3	74	9	micol	micol	PROPN
njb-3	74	10	et	et	PROPN
njb-3	74	11	al	al	PROPN
njb-3	74	12	.	.	PUNCT
njb-3	75	1	(	(	PUNCT
njb-3	75	2	2007	2007	NUM
njb-3	75	3	)	)	PUNCT
njb-3	75	4	and	and	CCONJ
njb-3	75	5	oyella	oyella	PROPN
njb-3	75	6	et	et	PROPN
njb-3	75	7	al	al	PROPN
njb-3	75	8	.	.	PUNCT
njb-3	75	9	(	(	PUNCT
njb-3	75	10	2012	2012	NUM
njb-3	75	11	)	)	PUNCT
njb-3	76	1	but	but	CCONJ
njb-3	76	2	,	,	PUNCT
njb-3	76	3	much	much	ADV
njb-3	76	4	higher	high	ADJ
njb-3	76	5	than	than	ADP
njb-3	76	6	nepal	nepal	ADJ
njb-3	76	7	j	j	PROPN
njb-3	76	8	biotechnol	biotechnol	PROPN
njb-3	76	9	.	.	PUNCT
njb-3	77	1	2021	2021	NUM
njb-3	77	2	dec.9	dec.9	NOUN
njb-3	77	3	(	(	PUNCT
njb-3	77	4	2	2	NUM
njb-3	77	5	):	):	PUNCT
njb-3	77	6	29	29	NUM
njb-3	77	7	-	-	SYM
njb-3	77	8	32	32	NUM
njb-3	77	9	khadka	khadka	NOUN
njb-3	77	10	et	et	PROPN
njb-3	77	11	al	al	PROPN
njb-3	77	12	.	.	PUNCT
njb-3	78	1	©	©	PROPN
njb-3	78	2	njb	njb	PROPN
njb-3	78	3	,	,	PUNCT
njb-3	78	4	bsn	bsn	PROPN
njb-3	78	5	31	31	NUM
njb-3	78	6	the	the	DET
njb-3	78	7	study	study	NOUN
njb-3	78	8	by	by	ADP
njb-3	78	9	lakoh	lakoh	PROPN
njb-3	78	10	et	et	PROPN
njb-3	78	11	al	al	PROPN
njb-3	78	12	.	.	PUNCT
njb-3	79	1	[	[	X
njb-3	79	2	9	9	NUM
njb-3	79	3	,	,	PUNCT
njb-3	79	4	11	11	NUM
njb-3	79	5	,	,	PUNCT
njb-3	79	6	12	12	NUM
njb-3	79	7	]	]	PUNCT
njb-3	79	8	.	.	PUNCT
njb-3	80	1	in	in	ADP
njb-3	80	2	one	one	NUM
njb-3	80	3	study	study	NOUN
njb-3	80	4	done	do	VERB
njb-3	80	5	by	by	ADP
njb-3	80	6	osazuwa	osazuwa	PROPN
njb-3	80	7	et	et	PROPN
njb-3	80	8	al	al	PROPN
njb-3	80	9	.	.	PUNCT
njb-3	81	1	the	the	DET
njb-3	81	2	prevalence	prevalence	NOUN
njb-3	81	3	rate	rate	NOUN
njb-3	81	4	was	be	AUX
njb-3	81	5	just	just	ADV
njb-3	81	6	12.7	12.7	NUM
njb-3	81	7	%	%	NOUN
njb-3	81	8	among	among	ADP
njb-3	81	9	150	150	NUM
njb-3	81	10	art	art	NOUN
njb-3	81	11	naïve	naïve	ADJ
njb-3	81	12	populations	population	NOUN
njb-3	81	13	,	,	PUNCT
njb-3	81	14	which	which	PRON
njb-3	81	15	is	be	AUX
njb-3	81	16	less	less	ADV
njb-3	81	17	as	as	ADP
njb-3	81	18	compared	compare	VERB
njb-3	81	19	to	to	ADP
njb-3	81	20	our	our	PRON
njb-3	81	21	study	study	NOUN
njb-3	81	22	[	[	PUNCT
njb-3	81	23	13	13	NUM
njb-3	81	24	]	]	PUNCT
njb-3	81	25	.	.	PUNCT
njb-3	82	1	art	art	NOUN
njb-3	82	2	naïve	naïve	PROPN
njb-3	82	3	refers	refer	VERB
njb-3	82	4	to	to	ADP
njb-3	82	5	a	a	DET
njb-3	82	6	stage	stage	NOUN
njb-3	82	7	before	before	ADP
njb-3	82	8	receiving	receive	VERB
njb-3	82	9	antiretroviral	antiretroviral	ADJ
njb-3	82	10	therapy	therapy	NOUN
njb-3	82	11	(	(	PUNCT
njb-3	82	12	art	art	NOUN
njb-3	82	13	)	)	PUNCT
njb-3	82	14	.	.	PUNCT
njb-3	83	1	it	it	PRON
njb-3	83	2	is	be	AUX
njb-3	83	3	believed	believe	VERB
njb-3	83	4	that	that	SCONJ
njb-3	83	5	persons	person	NOUN
njb-3	83	6	in	in	ADP
njb-3	83	7	art	art	NOUN
njb-3	83	8	have	have	VERB
njb-3	83	9	lower	low	ADJ
njb-3	83	10	risk	risk	NOUN
njb-3	83	11	of	of	ADP
njb-3	83	12	opportunistic	opportunistic	ADJ
njb-3	83	13	infection	infection	NOUN
njb-3	83	14	.	.	PUNCT
njb-3	84	1	however	however	ADV
njb-3	84	2	,	,	PUNCT
njb-3	84	3	the	the	DET
njb-3	84	4	data	datum	NOUN
njb-3	84	5	in	in	ADP
njb-3	84	6	our	our	PRON
njb-3	84	7	study	study	NOUN
njb-3	84	8	is	be	AUX
njb-3	84	9	much	much	ADV
njb-3	84	10	higher	high	ADJ
njb-3	84	11	as	as	SCONJ
njb-3	84	12	compared	compare	VERB
njb-3	84	13	to	to	PART
njb-3	84	14	study	study	VERB
njb-3	84	15	by	by	ADP
njb-3	84	16	osazuwa	osazuwa	PROPN
njb-3	84	17	et	et	PROPN
njb-3	84	18	al	al	PROPN
njb-3	84	19	.	.	PUNCT
njb-3	85	1	the	the	DET
njb-3	85	2	difference	difference	NOUN
njb-3	85	3	in	in	ADP
njb-3	85	4	data	datum	NOUN
njb-3	85	5	might	might	AUX
njb-3	85	6	be	be	AUX
njb-3	85	7	due	due	ADJ
njb-3	85	8	to	to	ADP
njb-3	85	9	the	the	DET
njb-3	85	10	difference	difference	NOUN
njb-3	85	11	in	in	ADP
njb-3	85	12	exposure	exposure	NOUN
njb-3	85	13	to	to	ADP
njb-3	85	14	the	the	DET
njb-3	85	15	causative	causative	ADJ
njb-3	85	16	agent	agent	NOUN
njb-3	85	17	of	of	ADP
njb-3	85	18	cryptococcosis	cryptococcosis	NOUN
njb-3	85	19	.	.	PUNCT
njb-3	86	1	the	the	DET
njb-3	86	2	ratio	ratio	NOUN
njb-3	86	3	of	of	ADP
njb-3	86	4	female	female	NOUN
njb-3	86	5	to	to	ADP
njb-3	86	6	male	male	ADJ
njb-3	86	7	hiv	hiv	PROPN
njb-3	86	8	patients	patient	NOUN
njb-3	86	9	in	in	ADP
njb-3	86	10	our	our	PRON
njb-3	86	11	study	study	NOUN
njb-3	86	12	was	be	AUX
njb-3	86	13	2:11	2:11	NUM
njb-3	86	14	.	.	PUNCT
njb-3	87	1	the	the	DET
njb-3	87	2	number	number	NOUN
njb-3	87	3	of	of	ADP
njb-3	87	4	males	male	NOUN
njb-3	87	5	72	72	NUM
njb-3	87	6	(	(	PUNCT
njb-3	87	7	72.8	72.8	NUM
njb-3	87	8	%	%	NOUN
njb-3	87	9	)	)	PUNCT
njb-3	87	10	were	be	AUX
njb-3	87	11	higher	high	ADJ
njb-3	87	12	than	than	ADP
njb-3	87	13	the	the	DET
njb-3	87	14	number	number	NOUN
njb-3	87	15	of	of	ADP
njb-3	87	16	females	female	NOUN
njb-3	87	17	27	27	NUM
njb-3	87	18	(	(	PUNCT
njb-3	87	19	27.2	27.2	NUM
njb-3	87	20	%	%	NOUN
njb-3	87	21	)	)	PUNCT
njb-3	87	22	.	.	PUNCT
njb-3	88	1	the	the	DET
njb-3	88	2	data	datum	NOUN
njb-3	88	3	is	be	AUX
njb-3	88	4	in	in	ADP
njb-3	88	5	contrary	contrary	ADJ
njb-3	88	6	to	to	ADP
njb-3	88	7	the	the	DET
njb-3	88	8	study	study	NOUN
njb-3	88	9	of	of	ADP
njb-3	88	10	geda	geda	PROPN
njb-3	88	11	et	et	PROPN
njb-3	88	12	al	al	PROPN
njb-3	88	13	.	.	PUNCT
njb-3	89	1	that	that	PRON
njb-3	89	2	reported	report	VERB
njb-3	89	3	higher	high	ADJ
njb-3	89	4	prevalence	prevalence	NOUN
njb-3	89	5	of	of	ADP
njb-3	89	6	hiv	hiv	PROPN
njb-3	89	7	infection	infection	NOUN
njb-3	89	8	in	in	ADP
njb-3	89	9	females	female	NOUN
njb-3	89	10	[	[	PUNCT
njb-3	89	11	14	14	NUM
njb-3	89	12	]	]	PUNCT
njb-3	89	13	.	.	PUNCT
njb-3	90	1	this	this	PRON
njb-3	90	2	may	may	AUX
njb-3	90	3	be	be	AUX
njb-3	90	4	due	due	ADJ
njb-3	90	5	to	to	ADP
njb-3	90	6	differences	difference	NOUN
njb-3	90	7	of	of	ADP
njb-3	90	8	exposure	exposure	NOUN
njb-3	90	9	as	as	ADV
njb-3	90	10	well	well	ADV
njb-3	90	11	as	as	ADP
njb-3	90	12	social	social	ADJ
njb-3	90	13	stigma	stigma	NOUN
njb-3	90	14	.	.	PUNCT
njb-3	91	1	higher	high	ADJ
njb-3	91	2	number	number	NOUN
njb-3	91	3	of	of	ADP
njb-3	91	4	hiv	hiv	PROPN
njb-3	91	5	-	-	PUNCT
njb-3	91	6	infected	infect	VERB
njb-3	91	7	males	male	NOUN
njb-3	91	8	as	as	SCONJ
njb-3	91	9	compared	compare	VERB
njb-3	91	10	to	to	ADP
njb-3	91	11	females	female	NOUN
njb-3	91	12	in	in	ADP
njb-3	91	13	nepal	nepal	ADJ
njb-3	91	14	might	might	AUX
njb-3	91	15	be	be	AUX
njb-3	91	16	another	another	DET
njb-3	91	17	reason	reason	NOUN
njb-3	91	18	for	for	ADP
njb-3	91	19	the	the	DET
njb-3	91	20	difference	difference	NOUN
njb-3	91	21	in	in	ADP
njb-3	91	22	enrollment	enrollment	NOUN
njb-3	91	23	of	of	ADP
njb-3	91	24	males	male	NOUN
njb-3	91	25	and	and	CCONJ
njb-3	91	26	females	female	NOUN
njb-3	91	27	in	in	ADP
njb-3	91	28	our	our	PRON
njb-3	91	29	study	study	NOUN
njb-3	91	30	[	[	PUNCT
njb-3	91	31	15	15	NUM
njb-3	91	32	]	]	SYM
njb-3	91	33	.	.	PUNCT
njb-3	92	1	fungal	fungal	ADJ
njb-3	92	2	culture	culture	PROPN
njb-3	92	3	is	be	AUX
njb-3	92	4	the	the	DET
njb-3	92	5	gold	gold	ADJ
njb-3	92	6	standard	standard	NOUN
njb-3	92	7	for	for	ADP
njb-3	92	8	the	the	DET
njb-3	92	9	detection	detection	NOUN
njb-3	92	10	of	of	ADP
njb-3	92	11	cryptococcus	cryptococcus	PROPN
njb-3	92	12	neoformans	neoformans	PROPN
njb-3	92	13	.	.	PUNCT
njb-3	93	1	however	however	ADV
njb-3	93	2	,	,	PUNCT
njb-3	93	3	some	some	DET
njb-3	93	4	literature	literature	NOUN
njb-3	93	5	suggest	suggest	VERB
njb-3	93	6	that	that	SCONJ
njb-3	93	7	the	the	DET
njb-3	93	8	latex	latex	NOUN
njb-3	93	9	agglutination	agglutination	NOUN
njb-3	93	10	test	test	NOUN
njb-3	93	11	for	for	ADP
njb-3	93	12	cryptococcal	cryptococcal	ADJ
njb-3	93	13	antigen	antigen	PROPN
njb-3	93	14	has	have	VERB
njb-3	93	15	100	100	NUM
njb-3	93	16	%	%	NOUN
njb-3	93	17	sensitivity	sensitivity	NOUN
njb-3	93	18	and	and	CCONJ
njb-3	93	19	96	96	NUM
njb-3	93	20	%	%	NOUN
njb-3	93	21	specificity	specificity	NOUN
njb-3	93	22	compared	compare	VERB
njb-3	93	23	to	to	ADP
njb-3	93	24	culture	culture	NOUN
njb-3	93	25	[	[	PUNCT
njb-3	93	26	10	10	NUM
njb-3	93	27	]	]	PUNCT
njb-3	93	28	.	.	PUNCT
njb-3	94	1	our	our	PRON
njb-3	94	2	study	study	NOUN
njb-3	94	3	shows	show	VERB
njb-3	94	4	that	that	SCONJ
njb-3	94	5	there	there	PRON
njb-3	94	6	is	be	VERB
njb-3	94	7	high	high	ADJ
njb-3	94	8	prevalence	prevalence	NOUN
njb-3	94	9	of	of	ADP
njb-3	94	10	cryptococcal	cryptococcal	ADJ
njb-3	94	11	antigenemia	antigenemia	NOUN
njb-3	94	12	among	among	ADP
njb-3	94	13	immunocompromised	immunocompromise	VERB
njb-3	94	14	hiv	hiv	PROPN
njb-3	94	15	positive	positive	ADJ
njb-3	94	16	individuals	individual	NOUN
njb-3	94	17	in	in	ADP
njb-3	94	18	nepal	nepal	NOUN
njb-3	94	19	.	.	PUNCT
njb-3	95	1	though	though	SCONJ
njb-3	95	2	our	our	PRON
njb-3	95	3	national	national	ADJ
njb-3	95	4	guidelines	guideline	NOUN
njb-3	95	5	do	do	AUX
njb-3	95	6	not	not	PART
njb-3	95	7	recommend	recommend	VERB
njb-3	95	8	cryptococcal	cryptococcal	ADJ
njb-3	95	9	screening	screening	NOUN
njb-3	95	10	and	and	CCONJ
njb-3	95	11	primary	primary	ADJ
njb-3	95	12	prophylaxis	prophylaxis	NOUN
njb-3	95	13	mandatory	mandatory	ADJ
njb-3	95	14	for	for	SCONJ
njb-3	95	15	every	every	DET
njb-3	95	16	hiv	hiv	PROPN
njb-3	95	17	infected	infect	VERB
njb-3	95	18	individuals	individual	NOUN
njb-3	95	19	having	have	VERB
njb-3	95	20	cd4	cd4	PROPN
njb-3	95	21	t	t	PROPN
njb-3	95	22	cell	cell	NOUN
njb-3	95	23	count	count	NOUN
njb-3	95	24	less	less	ADJ
njb-3	95	25	than	than	ADP
njb-3	95	26	100	100	NUM
njb-3	95	27	cells	cell	NOUN
njb-3	95	28	/	/	SYM
njb-3	95	29	mm3	mm3	NOUN
njb-3	95	30	,	,	PUNCT
njb-3	95	31	this	this	DET
njb-3	95	32	study	study	NOUN
njb-3	95	33	recommends	recommend	VERB
njb-3	95	34	testing	testing	NOUN
njb-3	95	35	for	for	ADP
njb-3	95	36	cryptococcal	cryptococcal	ADJ
njb-3	95	37	infection	infection	NOUN
njb-3	95	38	at	at	ADP
njb-3	95	39	least	least	ADJ
njb-3	95	40	by	by	ADP
njb-3	95	41	latex	latex	NOUN
njb-3	95	42	agglutination	agglutination	NOUN
njb-3	95	43	assay	assay	NOUN
njb-3	95	44	to	to	PART
njb-3	95	45	be	be	AUX
njb-3	95	46	made	make	VERB
njb-3	95	47	as	as	ADP
njb-3	95	48	a	a	DET
njb-3	95	49	routine	routine	ADJ
njb-3	95	50	test	test	NOUN
njb-3	95	51	for	for	ADP
njb-3	95	52	such	such	ADJ
njb-3	95	53	cases	case	NOUN
njb-3	95	54	.	.	PUNCT
njb-3	96	1	this	this	PRON
njb-3	96	2	may	may	AUX
njb-3	96	3	be	be	AUX
njb-3	96	4	helpful	helpful	ADJ
njb-3	96	5	in	in	ADP
njb-3	96	6	preventing	prevent	VERB
njb-3	96	7	morbidity	morbidity	NOUN
njb-3	96	8	and	and	CCONJ
njb-3	96	9	mortality	mortality	NOUN
njb-3	96	10	caused	cause	VERB
njb-3	96	11	due	due	ADP
njb-3	96	12	to	to	ADP
njb-3	96	13	meningitis	meningitis	PROPN
njb-3	96	14	among	among	ADP
njb-3	96	15	hiv	hiv	PROPN
njb-3	96	16	infected	infect	VERB
njb-3	96	17	individuals	individual	NOUN
njb-3	96	18	.	.	PUNCT
njb-3	97	1	conclusion	conclusion	NOUN
njb-3	97	2	the	the	DET
njb-3	97	3	study	study	NOUN
njb-3	97	4	revealed	reveal	VERB
njb-3	97	5	that	that	SCONJ
njb-3	97	6	18.2	18.2	NUM
njb-3	97	7	%	%	NOUN
njb-3	97	8	of	of	ADP
njb-3	97	9	people	people	NOUN
njb-3	97	10	living	live	VERB
njb-3	97	11	with	with	ADP
njb-3	97	12	hiv	hiv	PROPN
njb-3	97	13	in	in	ADP
njb-3	97	14	aids	aids	PROPN
njb-3	97	15	stage	stage	NOUN
njb-3	97	16	in	in	ADP
njb-3	97	17	nepal	nepal	ADJ
njb-3	97	18	are	be	AUX
njb-3	97	19	seropositive	seropositive	ADJ
njb-3	97	20	for	for	ADP
njb-3	97	21	the	the	DET
njb-3	97	22	cryptococcal	cryptococcal	ADJ
njb-3	97	23	antigen	antigen	PROPN
njb-3	97	24	.	.	PUNCT
njb-3	98	1	furthermore	furthermore	ADV
njb-3	98	2	,	,	PUNCT
njb-3	98	3	in	in	ADP
njb-3	98	4	absence	absence	NOUN
njb-3	98	5	of	of	ADP
njb-3	98	6	gold	gold	ADJ
njb-3	98	7	standard	standard	ADJ
njb-3	98	8	test	test	NOUN
njb-3	98	9	available	available	ADJ
njb-3	98	10	for	for	ADP
njb-3	98	11	detection	detection	NOUN
njb-3	98	12	of	of	ADP
njb-3	98	13	cryptococcal	cryptococcal	ADJ
njb-3	98	14	infection	infection	NOUN
njb-3	98	15	,	,	PUNCT
njb-3	98	16	serological	serological	ADJ
njb-3	98	17	antigen	antigen	NOUN
njb-3	98	18	screening	screening	NOUN
njb-3	98	19	by	by	ADP
njb-3	98	20	latex	latex	NOUN
njb-3	98	21	agglutination	agglutination	NOUN
njb-3	98	22	assay	assay	PROPN
njb-3	98	23	is	be	AUX
njb-3	98	24	helpful	helpful	ADJ
njb-3	98	25	to	to	PART
njb-3	98	26	detect	detect	VERB
njb-3	98	27	the	the	DET
njb-3	98	28	cases	case	NOUN
njb-3	98	29	of	of	ADP
njb-3	98	30	cryptococcosis	cryptococcosis	NOUN
njb-3	98	31	among	among	ADP
njb-3	98	32	immunocompromised	immunocompromise	VERB
njb-3	98	33	hiv	hiv	PROPN
njb-3	98	34	infected	infect	VERB
njb-3	98	35	individuals	individual	NOUN
njb-3	98	36	.	.	PUNCT
njb-3	99	1	abbreviations	abbreviation	NOUN
njb-3	99	2	hiv	hiv	PROPN
njb-3	99	3	:	:	PUNCT
njb-3	99	4	human	human	ADJ
njb-3	99	5	immunodeficiency	immunodeficiency	NOUN
njb-3	99	6	virus	virus	NOUN
njb-3	99	7	aids	aid	NOUN
njb-3	99	8	:	:	PUNCT
njb-3	99	9	acquired	acquire	VERB
njb-3	99	10	immuno	immuno	NOUN
njb-3	99	11	deficiency	deficiency	NOUN
njb-3	99	12	syndrome	syndrome	NOUN
njb-3	99	13	art	art	NOUN
njb-3	99	14	:	:	PUNCT
njb-3	99	15	antiretroviral	antiretroviral	ADJ
njb-3	99	16	therapy	therapy	NOUN
njb-3	99	17	cd4	cd4	PROPN
njb-3	99	18	:	:	PUNCT
njb-3	99	19	cluster	cluster	NOUN
njb-3	99	20	of	of	ADP
njb-3	99	21	differentiation	differentiation	NOUN
njb-3	99	22	4	4	NUM
njb-3	99	23	crag	crag	NOUN
njb-3	99	24	:	:	PUNCT
njb-3	99	25	cryptococcal	cryptococcal	ADJ
njb-3	99	26	antigen	antigen	PROPN
njb-3	99	27	lat	lat	PROPN
njb-3	99	28	:	:	PUNCT
njb-3	99	29	latex	latex	PROPN
njb-3	99	30	agglutination	agglutination	NOUN
njb-3	99	31	tests	test	VERB
njb-3	99	32	consent	consent	NOUN
njb-3	99	33	for	for	ADP
njb-3	99	34	publication	publication	NOUN
njb-3	99	35	not	not	PART
njb-3	99	36	applicable	applicable	ADJ
njb-3	99	37	competing	compete	VERB
njb-3	99	38	interests	interest	NOUN
njb-3	99	39	all	all	DET
njb-3	99	40	the	the	DET
njb-3	99	41	authors	author	NOUN
njb-3	99	42	declare	declare	VERB
njb-3	99	43	that	that	SCONJ
njb-3	99	44	they	they	PRON
njb-3	99	45	have	have	VERB
njb-3	99	46	no	no	DET
njb-3	99	47	any	any	DET
njb-3	99	48	competing	compete	VERB
njb-3	99	49	interests	interest	NOUN
njb-3	99	50	.	.	PUNCT
njb-3	100	1	author	author	NOUN
njb-3	100	2	’s	’s	PART
njb-3	100	3	contributions	contribution	NOUN
njb-3	100	4	sk	sk	PROPN
njb-3	100	5	,	,	PUNCT
njb-3	100	6	sd	sd	PROPN
njb-3	100	7	,	,	PUNCT
njb-3	100	8	skm	skm	PROPN
njb-3	100	9	,	,	PUNCT
njb-3	100	10	and	and	CCONJ
njb-3	100	11	rkm	rkm	NOUN
njb-3	100	12	were	be	AUX
njb-3	100	13	responsible	responsible	ADJ
njb-3	100	14	for	for	ADP
njb-3	100	15	study	study	NOUN
njb-3	100	16	design	design	NOUN
njb-3	100	17	,	,	PUNCT
njb-3	100	18	supervision	supervision	NOUN
njb-3	100	19	of	of	ADP
njb-3	100	20	work	work	NOUN
njb-3	100	21	,	,	PUNCT
njb-3	100	22	and	and	CCONJ
njb-3	100	23	guidance	guidance	NOUN
njb-3	100	24	.	.	PUNCT
njb-3	101	1	sk	sk	PROPN
njb-3	101	2	,	,	PUNCT
njb-3	101	3	sk	sk	PROPN
njb-3	101	4	,	,	PUNCT
njb-3	101	5	rp	rp	PROPN
njb-3	101	6	,	,	PUNCT
njb-3	101	7	rm	rm	PROPN
njb-3	101	8	,	,	PUNCT
njb-3	101	9	sd	sd	PROPN
njb-3	101	10	and	and	CCONJ
njb-3	101	11	jbb	jbb	PROPN
njb-3	101	12	performed	perform	VERB
njb-3	101	13	laboratory	laboratory	NOUN
njb-3	101	14	work	work	NOUN
njb-3	101	15	and	and	CCONJ
njb-3	101	16	data	datum	NOUN
njb-3	101	17	analysis	analysis	NOUN
njb-3	101	18	.	.	PUNCT
njb-3	102	1	sk	sk	PROPN
njb-3	102	2	,	,	PUNCT
njb-3	102	3	sk	sk	PROPN
njb-3	102	4	,	,	PUNCT
njb-3	102	5	rp	rp	PROPN
njb-3	102	6	,	,	PUNCT
njb-3	102	7	rm	rm	PROPN
njb-3	102	8	and	and	CCONJ
njb-3	102	9	sd	sd	NOUN
njb-3	102	10	prepared	prepare	VERB
njb-3	102	11	the	the	DET
njb-3	102	12	draft	draft	NOUN
njb-3	102	13	and	and	CCONJ
njb-3	102	14	wrote	write	VERB
njb-3	102	15	the	the	DET
njb-3	102	16	manuscript	manuscript	NOUN
njb-3	102	17	.	.	PUNCT
njb-3	103	1	finally	finally	ADV
njb-3	103	2	,	,	PUNCT
njb-3	103	3	all	all	DET
njb-3	103	4	the	the	DET
njb-3	103	5	authors	author	NOUN
njb-3	103	6	read	read	VERB
njb-3	103	7	the	the	DET
njb-3	103	8	manuscript	manuscript	NOUN
njb-3	103	9	and	and	CCONJ
njb-3	103	10	approved	approve	VERB
njb-3	103	11	for	for	ADP
njb-3	103	12	publication	publication	NOUN
njb-3	103	13	.	.	PUNCT
njb-3	104	1	acknowledgment	acknowledgment	VERB
njb-3	104	2	we	we	PRON
njb-3	104	3	would	would	AUX
njb-3	104	4	like	like	VERB
njb-3	104	5	to	to	PART
njb-3	104	6	acknowledge	acknowledge	VERB
njb-3	104	7	the	the	DET
njb-3	104	8	all	all	DET
njb-3	104	9	staffs	staff	NOUN
njb-3	104	10	of	of	ADP
njb-3	104	11	hiv	hiv	PROPN
njb-3	104	12	reference	reference	NOUN
njb-3	104	13	unit	unit	NOUN
njb-3	104	14	,	,	PUNCT
njb-3	104	15	national	national	ADJ
njb-3	104	16	public	public	ADJ
njb-3	104	17	health	health	PROPN
njb-3	104	18	laboratory	laboratory	NOUN
njb-3	104	19	,	,	PUNCT
njb-3	104	20	nepal	nepal	ADJ
njb-3	104	21	for	for	ADP
njb-3	104	22	their	their	PRON
njb-3	104	23	valuable	valuable	ADJ
njb-3	104	24	support	support	NOUN
njb-3	104	25	in	in	ADP
njb-3	104	26	completing	complete	VERB
njb-3	104	27	this	this	DET
njb-3	104	28	work	work	NOUN
njb-3	104	29	ethical	ethical	ADJ
njb-3	104	30	approval	approval	NOUN
njb-3	104	31	and	and	CCONJ
njb-3	104	32	consent	consent	VERB
njb-3	104	33	ethical	ethical	ADJ
njb-3	104	34	approval	approval	NOUN
njb-3	104	35	was	be	AUX
njb-3	104	36	taken	take	VERB
njb-3	104	37	from	from	ADP
njb-3	104	38	nepal	nepal	ADJ
njb-3	104	39	health	health	NOUN
njb-3	104	40	research	research	PROPN
njb-3	104	41	council	council	NOUN
njb-3	104	42	(	(	PUNCT
njb-3	104	43	ref	ref	VERB
njb-3	104	44	no	no	NOUN
njb-3	104	45	.	.	NOUN
njb-3	104	46	892	892	NUM
njb-3	104	47	)	)	PUNCT
njb-3	104	48	before	before	ADP
njb-3	104	49	carrying	carry	VERB
njb-3	104	50	out	out	ADP
njb-3	104	51	this	this	DET
njb-3	104	52	study	study	NOUN
njb-3	104	53	references	reference	NOUN
njb-3	104	54	1	1	NUM
njb-3	104	55	.	.	PUNCT
njb-3	105	1	osazuwa	osazuwa	PROPN
njb-3	105	2	f	f	PROPN
njb-3	105	3	,	,	PUNCT
njb-3	105	4	dirisu	dirisu	PROPN
njb-3	105	5	jo	jo	PROPN
njb-3	105	6	,	,	PUNCT
njb-3	105	7	okuonghae	okuonghae	PROPN
njb-3	105	8	pe	pe	PROPN
njb-3	105	9	,	,	PUNCT
njb-3	105	10	ugbebor	ugbebor	PROPN
njb-3	105	11	o.	o.	PROPN
njb-3	105	12	screening	screening	NOUN
njb-3	105	13	for	for	ADP
njb-3	105	14	cryptococcal	cryptococcal	ADJ
njb-3	105	15	antigenemia	antigenemia	NOUN
njb-3	105	16	in	in	ADP
njb-3	105	17	anti	anti	ADJ
njb-3	105	18	-	-	ADJ
njb-3	105	19	retroviral	retroviral	ADJ
njb-3	105	20	naïve	naïve	ADJ
njb-3	105	21	aids	aids	PROPN
njb-3	105	22	patients	patient	NOUN
njb-3	105	23	in	in	ADP
njb-3	105	24	benin	benin	PROPN
njb-3	105	25	city	city	PROPN
njb-3	105	26	,	,	PUNCT
njb-3	105	27	nigeria	nigeria	PROPN
njb-3	105	28	.	.	PROPN
njb-3	105	29	oman	oman	PROPN
njb-3	105	30	medical	medical	PROPN
njb-3	105	31	journal	journal	PROPN
njb-3	105	32	.	.	PUNCT
njb-3	106	1	2012;27(3):228	2012;27(3):228	NUM
njb-3	106	2	.	.	PUNCT
njb-3	106	3	2	2	NUM
njb-3	106	4	.	.	X
njb-3	106	5	rajasingham	rajasingham	PROPN
njb-3	106	6	r	r	PROPN
njb-3	106	7	,	,	PUNCT
njb-3	106	8	smith	smith	PROPN
njb-3	106	9	rm	rm	PROPN
njb-3	106	10	,	,	PUNCT
njb-3	106	11	park	park	PROPN
njb-3	106	12	bj	bj	PROPN
njb-3	106	13	,	,	PUNCT
njb-3	106	14	jarvis	jarvis	PROPN
njb-3	106	15	jn	jn	PROPN
njb-3	106	16	,	,	PUNCT
njb-3	106	17	govender	govender	PROPN
njb-3	106	18	np	np	PROPN
njb-3	106	19	,	,	PUNCT
njb-3	106	20	chiller	chiller	PROPN
njb-3	106	21	tm	tm	PROPN
njb-3	106	22	,	,	PUNCT
njb-3	106	23	et	et	PROPN
njb-3	106	24	al	al	PROPN
njb-3	106	25	.	.	PUNCT
njb-3	107	1	global	global	ADJ
njb-3	107	2	burden	burden	NOUN
njb-3	107	3	of	of	ADP
njb-3	107	4	disease	disease	NOUN
njb-3	107	5	of	of	ADP
njb-3	107	6	hiv	hiv	PROPN
njb-3	107	7	-	-	PUNCT
njb-3	107	8	associated	associate	VERB
njb-3	107	9	cryptococcal	cryptococcal	PROPN
njb-3	107	10	meningitis	meningitis	PROPN
njb-3	107	11	:	:	PUNCT
njb-3	107	12	an	an	DET
njb-3	107	13	updated	update	VERB
njb-3	107	14	analysis	analysis	NOUN
njb-3	107	15	.	.	PUNCT
njb-3	108	1	the	the	DET
njb-3	108	2	lancet	lancet	PROPN
njb-3	108	3	infectious	infectious	ADJ
njb-3	108	4	diseases	disease	NOUN
njb-3	108	5	.	.	PUNCT
njb-3	109	1	2017;17(8):873	2017;17(8):873	NOUN
njb-3	109	2	-	-	SYM
njb-3	109	3	81	81	NUM
njb-3	109	4	.	.	NUM
njb-3	109	5	3	3	X
njb-3	109	6	.	.	X
njb-3	109	7	park	park	PROPN
njb-3	109	8	bj	bj	PROPN
njb-3	109	9	,	,	PUNCT
njb-3	109	10	wannemuehler	wannemuehler	PROPN
njb-3	109	11	ka	ka	PROPN
njb-3	109	12	,	,	PUNCT
njb-3	109	13	marston	marston	PROPN
njb-3	109	14	bj	bj	PROPN
njb-3	109	15	,	,	PUNCT
njb-3	109	16	govender	govender	PROPN
njb-3	109	17	n	n	NOUN
njb-3	109	18	,	,	PUNCT
njb-3	109	19	pappas	pappas	PROPN
njb-3	109	20	pg	pg	PROPN
njb-3	109	21	,	,	PUNCT
njb-3	109	22	chiller	chiller	PROPN
njb-3	109	23	tm	tm	PROPN
njb-3	109	24	.	.	PROPN
njb-3	109	25	estimation	estimation	PROPN
njb-3	109	26	of	of	ADP
njb-3	109	27	the	the	DET
njb-3	109	28	current	current	ADJ
njb-3	109	29	global	global	ADJ
njb-3	109	30	burden	burden	NOUN
njb-3	109	31	of	of	ADP
njb-3	109	32	cryptococcal	cryptococcal	ADJ
njb-3	109	33	meningitis	meningitis	PROPN
njb-3	109	34	among	among	ADP
njb-3	109	35	persons	person	NOUN
njb-3	109	36	living	live	VERB
njb-3	109	37	with	with	ADP
njb-3	109	38	hiv	hiv	PROPN
njb-3	109	39	/	/	SYM
njb-3	109	40	aids	aid	NOUN
njb-3	109	41	.	.	PUNCT
njb-3	110	1	aids	aid	NOUN
njb-3	110	2	.	.	PUNCT
njb-3	111	1	2009;23(4):525	2009;23(4):525	NOUN
njb-3	111	2	-	-	SYM
njb-3	111	3	30	30	NUM
njb-3	111	4	.	.	NUM
njb-3	111	5	4	4	NUM
njb-3	111	6	.	.	X
njb-3	111	7	smith	smith	PROPN
njb-3	111	8	rm	rm	PROPN
njb-3	111	9	,	,	PUNCT
njb-3	111	10	nguyen	nguyen	PROPN
njb-3	111	11	ta	ta	PROPN
njb-3	111	12	,	,	PUNCT
njb-3	111	13	ha	ha	INTJ
njb-3	111	14	htt	htt	PROPN
njb-3	111	15	,	,	PUNCT
njb-3	111	16	thang	thang	ADP
njb-3	111	17	ph	ph	NOUN
njb-3	111	18	,	,	PUNCT
njb-3	111	19	thuy	thuy	PROPN
njb-3	111	20	c	c	PROPN
njb-3	111	21	,	,	PUNCT
njb-3	111	22	xuan	xuan	PROPN
njb-3	111	23	lien	lien	PROPN
njb-3	111	24	t	t	PROPN
njb-3	111	25	,	,	PUNCT
njb-3	111	26	et	et	PROPN
njb-3	111	27	al	al	PROPN
njb-3	111	28	.	.	PUNCT
njb-3	111	29	prevalence	prevalence	NOUN
njb-3	111	30	of	of	ADP
njb-3	111	31	cryptococcal	cryptococcal	ADJ
njb-3	111	32	antigenemia	antigenemia	NOUN
njb-3	111	33	and	and	CCONJ
njb-3	111	34	costeffectiveness	costeffectiveness	NOUN
njb-3	111	35	of	of	ADP
njb-3	111	36	a	a	DET
njb-3	111	37	cryptococcal	cryptococcal	ADJ
njb-3	111	38	antigen	antigen	NOUN
njb-3	111	39	screening	screening	NOUN
njb-3	111	40	program	program	NOUN
njb-3	111	41	–	–	PUNCT
njb-3	111	42	vietnam	vietnam	PROPN
njb-3	111	43	.	.	PUNCT
njb-3	112	1	plos	plos	PROPN
njb-3	112	2	one	one	PROPN
njb-3	112	3	.	.	PUNCT
njb-3	112	4	2013;8(4):e62213	2013;8(4):e62213	NUM
njb-3	112	5	.	.	PUNCT
njb-3	113	1	5	5	NUM
njb-3	113	2	.	.	X
njb-3	114	1	who	who	PRON
njb-3	114	2	.	.	PUNCT
njb-3	115	1	guideline	guideline	NOUN
njb-3	115	2	for	for	ADP
njb-3	115	3	the	the	DET
njb-3	115	4	diagnosis	diagnosis	NOUN
njb-3	115	5	,	,	PUNCT
njb-3	115	6	prevention	prevention	NOUN
njb-3	115	7	and	and	CCONJ
njb-3	115	8	management	management	NOUN
njb-3	115	9	of	of	ADP
njb-3	115	10	cryptococcal	cryptococcal	ADJ
njb-3	115	11	disease	disease	NOUN
njb-3	115	12	in	in	ADP
njb-3	115	13	hiv	hiv	PROPN
njb-3	115	14	-	-	PUNCT
njb-3	115	15	infected	infect	VERB
njb-3	115	16	adults	adult	NOUN
njb-3	115	17	,	,	PUNCT
njb-3	115	18	adolescents	adolescent	NOUN
njb-3	115	19	and	and	CCONJ
njb-3	115	20	children	child	NOUN
njb-3	115	21	.	.	PUNCT
njb-3	116	1	world	world	NOUN
njb-3	116	2	health	health	NOUN
njb-3	116	3	organization	organization	NOUN
njb-3	116	4	(	(	PUNCT
njb-3	116	5	who	who	PRON
njb-3	116	6	)	)	PUNCT
njb-3	116	7	;	;	PUNCT
njb-3	116	8	2018	2018	NUM
njb-3	116	9	.	.	PUNCT
njb-3	117	1	6	6	NUM
njb-3	117	2	.	.	PUNCT
njb-3	117	3	saha	saha	PROPN
njb-3	117	4	dc	dc	PROPN
njb-3	117	5	,	,	PUNCT
njb-3	117	6	xess	xess	PROPN
njb-3	117	7	i	i	PROPN
njb-3	117	8	,	,	PUNCT
njb-3	117	9	biswas	biswa	VERB
njb-3	117	10	a	a	DET
njb-3	117	11	,	,	PUNCT
njb-3	117	12	bhowmik	bhowmik	ADJ
njb-3	117	13	dm	dm	PROPN
njb-3	117	14	,	,	PUNCT
njb-3	117	15	padma	padma	PROPN
njb-3	117	16	m.	m.	NOUN
njb-3	117	17	detection	detection	NOUN
njb-3	117	18	of	of	ADP
njb-3	117	19	cryptococcus	cryptococcus	PROPN
njb-3	117	20	by	by	ADP
njb-3	117	21	conventional	conventional	ADJ
njb-3	117	22	,	,	PUNCT
njb-3	117	23	serological	serological	ADJ
njb-3	117	24	and	and	CCONJ
njb-3	117	25	molecular	molecular	ADJ
njb-3	117	26	methods	method	NOUN
njb-3	117	27	.	.	PUNCT
njb-3	118	1	journal	journal	PROPN
njb-3	118	2	of	of	ADP
njb-3	118	3	medical	medical	ADJ
njb-3	118	4	microbiology	microbiology	NOUN
njb-3	118	5	.	.	PUNCT
njb-3	119	1	2009;58(8):1098	2009;58(8):1098	NUM
njb-3	119	2	-	-	SYM
njb-3	119	3	105	105	NUM
njb-3	119	4	.	.	NUM
njb-3	119	5	7	7	NUM
njb-3	119	6	.	.	PROPN
njb-3	119	7	letang	letang	PROPN
njb-3	119	8	e	e	PROPN
njb-3	119	9	,	,	PUNCT
njb-3	119	10	müller	müller	PROPN
njb-3	119	11	mc	mc	PROPN
njb-3	119	12	,	,	PUNCT
njb-3	119	13	ntamatungiro	ntamatungiro	PROPN
njb-3	119	14	aj	aj	PROPN
njb-3	119	15	,	,	PUNCT
njb-3	119	16	kimera	kimera	PROPN
njb-3	119	17	n	n	PROPN
njb-3	119	18	,	,	PUNCT
njb-3	119	19	faini	faini	PROPN
njb-3	119	20	d	d	PROPN
njb-3	119	21	,	,	PUNCT
njb-3	119	22	furrer	furrer	NOUN
njb-3	119	23	h	h	PROPN
njb-3	119	24	,	,	PUNCT
njb-3	119	25	battegay	battegay	PROPN
njb-3	119	26	m	m	PROPN
njb-3	119	27	,	,	PUNCT
njb-3	119	28	tanner	tanner	NOUN
njb-3	119	29	m	m	PROPN
njb-3	119	30	,	,	PUNCT
njb-3	119	31	hatz	hatz	PROPN
njb-3	119	32	c	c	PROPN
njb-3	119	33	,	,	PUNCT
njb-3	119	34	boulware	boulware	PROPN
njb-3	119	35	dr	dr	PROPN
njb-3	119	36	,	,	PUNCT
njb-3	119	37	glass	glass	PROPN
njb-3	119	38	tr	tr	VERB
njb-3	119	39	.	.	PROPN
njb-3	119	40	cryptococcal	cryptococcal	ADJ
njb-3	119	41	antigenemia	antigenemia	NOUN
njb-3	119	42	in	in	ADP
njb-3	119	43	immunocompromised	immunocompromise	VERB
njb-3	119	44	human	human	ADJ
njb-3	119	45	immunodeficiency	immunodeficiency	NOUN
njb-3	119	46	virus	virus	NOUN
njb-3	119	47	patients	patient	NOUN
njb-3	119	48	in	in	ADP
njb-3	119	49	rural	rural	ADJ
njb-3	119	50	tanzania	tanzania	NOUN
njb-3	119	51	:	:	PUNCT
njb-3	119	52	a	a	DET
njb-3	119	53	preventable	preventable	ADJ
njb-3	119	54	cause	cause	NOUN
njb-3	119	55	of	of	ADP
njb-3	119	56	early	early	ADJ
njb-3	119	57	mortality	mortality	NOUN
njb-3	119	58	.	.	PUNCT
njb-3	120	1	inopen	inopen	PROPN
njb-3	120	2	forum	forum	PROPN
njb-3	120	3	infectious	infectious	ADJ
njb-3	120	4	diseases	disease	NOUN
njb-3	120	5	2015	2015	NUM
njb-3	120	6	apr	apr	NOUN
njb-3	120	7	1	1	NUM
njb-3	120	8	(	(	PUNCT
njb-3	120	9	vol	vol	NOUN
njb-3	120	10	.	.	PROPN
njb-3	120	11	2	2	NUM
njb-3	120	12	,	,	PUNCT
njb-3	120	13	no	no	NOUN
njb-3	120	14	.	.	NOUN
njb-3	120	15	2	2	NUM
njb-3	120	16	)	)	PUNCT
njb-3	120	17	.	.	PUNCT
njb-3	121	1	oxford	oxford	PROPN
njb-3	121	2	university	university	PROPN
njb-3	121	3	press	press	PROPN
njb-3	121	4	.	.	PUNCT
njb-3	122	1	8	8	X
njb-3	122	2	.	.	PUNCT
njb-3	122	3	ezenabike	ezenabike	PROPN
njb-3	122	4	c	c	PROPN
njb-3	122	5	,	,	PUNCT
njb-3	122	6	ashaka	ashaka	PROPN
njb-3	122	7	os	os	PROPN
njb-3	122	8	,	,	PUNCT
njb-3	122	9	omoare	omoare	PROPN
njb-3	122	10	aa	aa	PROPN
njb-3	122	11	,	,	PUNCT
njb-3	122	12	fadeyi	fadeyi	VERB
njb-3	122	13	a	a	PRON
njb-3	122	14	,	,	PUNCT
njb-3	122	15	salami	salami	PROPN
njb-3	122	16	ak	ak	PROPN
njb-3	122	17	,	,	PUNCT
njb-3	122	18	agbede	agbede	NOUN
njb-3	122	19	oo	oo	ADV
njb-3	122	20	.	.	PUNCT
njb-3	123	1	cryptococcal	cryptococcal	ADJ
njb-3	123	2	antigen	antigen	PROPN
njb-3	123	3	among	among	ADP
njb-3	123	4	hiv1	hiv1	PROPN
njb-3	123	5	-	-	PUNCT
njb-3	123	6	infected	infect	VERB
njb-3	123	7	individuals	individual	NOUN
njb-3	123	8	in	in	ADP
njb-3	123	9	north	north	NOUN
njb-3	123	10	-	-	PUNCT
njb-3	123	11	central	central	PROPN
njb-3	123	12	nigeria	nigeria	PROPN
njb-3	123	13	.	.	PROPN
njb-3	124	1	current	current	ADJ
njb-3	124	2	medical	medical	ADJ
njb-3	124	3	mycology	mycology	NOUN
njb-3	124	4	.	.	PUNCT
njb-3	124	5	2020	2020	NUM
njb-3	124	6	;	;	PUNCT
njb-3	124	7	6(2):43	6(2):43	PROPN
njb-3	124	8	.	.	PROPN
njb-3	124	9	nepal	nepal	PROPN
njb-3	124	10	j	j	PROPN
njb-3	124	11	biotechnol	biotechnol	PROPN
njb-3	124	12	.	.	PUNCT
njb-3	125	1	2021	2021	NUM
njb-3	125	2	dec.9	dec.9	NOUN
njb-3	125	3	(	(	PUNCT
njb-3	125	4	2	2	NUM
njb-3	125	5	):	):	PUNCT
njb-3	125	6	29	29	NUM
njb-3	125	7	-	-	SYM
njb-3	125	8	32	32	NUM
njb-3	125	9	khadka	khadka	NOUN
njb-3	125	10	et	et	PROPN
njb-3	125	11	al	al	PROPN
njb-3	125	12	.	.	PUNCT
njb-3	126	1	©	©	PROPN
njb-3	126	2	njb	njb	PROPN
njb-3	126	3	,	,	PUNCT
njb-3	126	4	bsn	bsn	PROPN
njb-3	126	5	32	32	NUM
njb-3	126	6	9	9	NUM
njb-3	126	7	.	.	PUNCT
njb-3	127	1	lakoh	lakoh	PROPN
njb-3	127	2	s	s	PROPN
njb-3	127	3	,	,	PUNCT
njb-3	127	4	rickman	rickman	PROPN
njb-3	127	5	h	h	PROPN
njb-3	127	6	,	,	PUNCT
njb-3	127	7	sesay	sesay	PROPN
njb-3	127	8	m	m	PROPN
njb-3	127	9	,	,	PUNCT
njb-3	127	10	kenneh	kenneh	PROPN
njb-3	127	11	s	s	PROPN
njb-3	127	12	,	,	PUNCT
njb-3	127	13	burke	burke	PROPN
njb-3	127	14	r	r	PROPN
njb-3	127	15	,	,	PUNCT
njb-3	127	16	baldeh	baldeh	PROPN
njb-3	127	17	m	m	PROPN
njb-3	127	18	,	,	PUNCT
njb-3	127	19	et	et	PROPN
njb-3	127	20	al	al	PROPN
njb-3	127	21	.	.	PUNCT
njb-3	128	1	prevalence	prevalence	NOUN
njb-3	128	2	and	and	CCONJ
njb-3	128	3	mortality	mortality	NOUN
njb-3	128	4	of	of	ADP
njb-3	128	5	cryptococcal	cryptococcal	ADJ
njb-3	128	6	disease	disease	NOUN
njb-3	128	7	in	in	ADP
njb-3	128	8	adults	adult	NOUN
njb-3	128	9	with	with	ADP
njb-3	128	10	advanced	advanced	ADJ
njb-3	128	11	hiv	hiv	PROPN
njb-3	128	12	in	in	ADP
njb-3	128	13	an	an	DET
njb-3	128	14	urban	urban	ADJ
njb-3	128	15	tertiary	tertiary	ADJ
njb-3	128	16	hospital	hospital	NOUN
njb-3	128	17	in	in	ADP
njb-3	128	18	sierra	sierra	PROPN
njb-3	128	19	leone	leone	PROPN
njb-3	128	20	:	:	PUNCT
njb-3	128	21	a	a	DET
njb-3	128	22	prospective	prospective	ADJ
njb-3	128	23	study	study	NOUN
njb-3	128	24	.	.	PUNCT
njb-3	129	1	bmc	bmc	PROPN
njb-3	129	2	infectious	infectious	ADJ
njb-3	129	3	diseases	disease	NOUN
njb-3	129	4	.	.	PUNCT
njb-3	130	1	2020;20(1):1	2020;20(1):1	NUM
njb-3	130	2	-	-	SYM
njb-3	130	3	7	7	NUM
njb-3	130	4	.	.	NUM
njb-3	130	5	10	10	NUM
njb-3	130	6	.	.	PUNCT
njb-3	131	1	crag	crag	PROPN
njb-3	131	2	®	®	PROPN
njb-3	131	3	lfa	lfa	PROPN
njb-3	131	4	cryptococcal	cryptococcal	PROPN
njb-3	131	5	antigen	antigen	PROPN
njb-3	131	6	lateral	lateral	ADJ
njb-3	131	7	flow	flow	NOUN
njb-3	131	8	assay	assay	NOUN
njb-3	131	9	for	for	ADP
njb-3	131	10	the	the	DET
njb-3	131	11	detection	detection	NOUN
njb-3	131	12	of	of	ADP
njb-3	131	13	cryptococcal	cryptococcal	ADJ
njb-3	131	14	antigen	antigen	PROPN
njb-3	131	15	.	.	PUNCT
njb-3	132	1	immy	immy	PROPN
njb-3	132	2	.	.	PROPN
njb-3	133	1	11	11	NUM
njb-3	133	2	.	.	PUNCT
njb-3	133	3	micol	micol	PROPN
njb-3	133	4	r	r	PROPN
njb-3	133	5	,	,	PUNCT
njb-3	133	6	lortholary	lortholary	PROPN
njb-3	133	7	o	o	PROPN
njb-3	133	8	,	,	PUNCT
njb-3	133	9	sar	sar	PROPN
njb-3	133	10	b	b	PROPN
njb-3	133	11	,	,	PUNCT
njb-3	133	12	laureillard	laureillard	NOUN
njb-3	133	13	d	d	PROPN
njb-3	133	14	,	,	PUNCT
njb-3	133	15	ngeth	ngeth	PROPN
njb-3	133	16	c	c	PROPN
njb-3	133	17	,	,	PUNCT
njb-3	133	18	dousset	dousset	VERB
njb-3	133	19	j	j	PROPN
njb-3	133	20	-	-	PUNCT
njb-3	133	21	p	p	PROPN
njb-3	133	22	,	,	PUNCT
njb-3	133	23	et	et	PROPN
njb-3	133	24	al	al	PROPN
njb-3	133	25	.	.	PUNCT
njb-3	134	1	prevalence	prevalence	NOUN
njb-3	134	2	,	,	PUNCT
njb-3	134	3	determinants	determinant	NOUN
njb-3	134	4	of	of	ADP
njb-3	134	5	positivity	positivity	NOUN
njb-3	134	6	,	,	PUNCT
njb-3	134	7	and	and	CCONJ
njb-3	134	8	clinical	clinical	ADJ
njb-3	134	9	utility	utility	NOUN
njb-3	134	10	of	of	ADP
njb-3	134	11	cryptococcal	cryptococcal	ADJ
njb-3	134	12	antigenemia	antigenemia	NOUN
njb-3	134	13	in	in	ADP
njb-3	134	14	cambodian	cambodian	PROPN
njb-3	134	15	hiv	hiv	PROPN
njb-3	134	16	-	-	PUNCT
njb-3	134	17	infected	infect	VERB
njb-3	134	18	patients	patient	NOUN
njb-3	134	19	.	.	PUNCT
njb-3	135	1	jaids	jaids	PROPN
njb-3	135	2	journal	journal	PROPN
njb-3	135	3	of	of	ADP
njb-3	135	4	acquired	acquire	VERB
njb-3	135	5	immune	immune	ADJ
njb-3	135	6	deficiency	deficiency	NOUN
njb-3	135	7	syndromes	syndrome	NOUN
njb-3	135	8	.	.	PUNCT
njb-3	136	1	2007;45(5):555	2007;45(5):555	NUM
njb-3	136	2	-	-	SYM
njb-3	136	3	9	9	NUM
njb-3	136	4	.	.	NUM
njb-3	136	5	12	12	NUM
njb-3	136	6	.	.	PUNCT
njb-3	137	1	oyella	oyella	PROPN
njb-3	137	2	j	j	PROPN
njb-3	137	3	,	,	PUNCT
njb-3	137	4	meya	meya	PROPN
njb-3	137	5	d	d	PROPN
njb-3	137	6	,	,	PUNCT
njb-3	137	7	bajunirwe	bajunirwe	PROPN
njb-3	137	8	f	f	PROPN
njb-3	137	9	,	,	PUNCT
njb-3	137	10	kamya	kamya	PROPN
njb-3	137	11	mr	mr	PROPN
njb-3	137	12	.	.	PROPN
njb-3	137	13	prevalence	prevalence	PROPN
njb-3	137	14	and	and	CCONJ
njb-3	137	15	factors	factor	NOUN
njb-3	137	16	associated	associate	VERB
njb-3	137	17	with	with	ADP
njb-3	137	18	cryptococcal	cryptococcal	ADJ
njb-3	137	19	antigenemia	antigenemia	NOUN
njb-3	137	20	among	among	ADP
njb-3	137	21	severely	severely	ADV
njb-3	137	22	immunosuppressed	immunosuppressed	ADJ
njb-3	137	23	hiv	hiv	PROPN
njb-3	137	24	-	-	PUNCT
njb-3	137	25	infected	infect	VERB
njb-3	137	26	adults	adult	NOUN
njb-3	137	27	in	in	ADP
njb-3	137	28	uganda	uganda	NOUN
njb-3	137	29	:	:	PUNCT
njb-3	137	30	a	a	DET
njb-3	137	31	crosssectional	crosssectional	ADJ
njb-3	137	32	study	study	NOUN
njb-3	137	33	.	.	PUNCT
njb-3	138	1	journal	journal	PROPN
njb-3	138	2	of	of	ADP
njb-3	138	3	the	the	DET
njb-3	138	4	international	international	ADJ
njb-3	138	5	aids	aids	PROPN
njb-3	138	6	society	society	NOUN
njb-3	138	7	.	.	PUNCT
njb-3	139	1	2012;15(1):1	2012;15(1):1	NUM
njb-3	139	2	-	-	SYM
njb-3	139	3	7	7	NUM
njb-3	139	4	.	.	NUM
njb-3	139	5	13	13	NUM
njb-3	139	6	.	.	PUNCT
njb-3	140	1	osazuwa	osazuwa	PROPN
njb-3	140	2	of	of	ADP
njb-3	140	3	,	,	PUNCT
njb-3	140	4	dirisu	dirisu	PROPN
njb-3	140	5	o	o	PROPN
njb-3	140	6	,	,	PUNCT
njb-3	140	7	okuonghae	okuonghae	PROPN
njb-3	140	8	e.	e.	PROPN
njb-3	140	9	cryptococcal	cryptococcal	PROPN
njb-3	140	10	antigenemia	antigenemia	NOUN
njb-3	140	11	in	in	ADP
njb-3	140	12	anti	anti	ADJ
njb-3	140	13	-	-	ADJ
njb-3	140	14	retroviral	retroviral	ADJ
njb-3	140	15	naive	naive	ADJ
njb-3	140	16	aids	aid	NOUN
njb-3	140	17	patients	patient	NOUN
njb-3	140	18	:	:	PUNCT
njb-3	140	19	prevalence	prevalence	NOUN
njb-3	140	20	and	and	CCONJ
njb-3	140	21	its	its	PRON
njb-3	140	22	association	association	NOUN
njb-3	140	23	with	with	ADP
njb-3	140	24	cd4	cd4	PROPN
njb-3	140	25	cell	cell	NOUN
njb-3	140	26	count	count	NOUN
njb-3	140	27	.	.	PUNCT
njb-3	141	1	acta	acta	PROPN
njb-3	141	2	medica	medica	PROPN
njb-3	141	3	iranica	iranica	PROPN
njb-3	141	4	.	.	PUNCT
njb-3	142	1	2012:344	2012:344	NUM
njb-3	142	2	-	-	SYM
njb-3	142	3	7	7	NUM
njb-3	142	4	.	.	NUM
njb-3	142	5	14	14	NUM
njb-3	142	6	.	.	PUNCT
njb-3	143	1	geda	geda	PROPN
njb-3	143	2	n	n	PROPN
njb-3	143	3	,	,	PUNCT
njb-3	143	4	beyene	beyene	PROPN
njb-3	143	5	t	t	PROPN
njb-3	143	6	,	,	PUNCT
njb-3	143	7	dabsu	dabsu	PROPN
njb-3	143	8	r	r	PROPN
njb-3	143	9	,	,	PUNCT
njb-3	143	10	mengist	mengist	ADJ
njb-3	143	11	hm	hm	INTJ
njb-3	143	12	.	.	PUNCT
njb-3	143	13	prevalence	prevalence	NOUN
njb-3	143	14	of	of	ADP
njb-3	143	15	cryptococcal	cryptococcal	ADJ
njb-3	143	16	antigenemia	antigenemia	NOUN
njb-3	143	17	and	and	CCONJ
njb-3	143	18	associated	associate	VERB
njb-3	143	19	factors	factor	NOUN
njb-3	143	20	among	among	ADP
njb-3	143	21	hiv	hiv	PROPN
njb-3	143	22	/	/	SYM
njb-3	143	23	aids	aids	PROPN
njb-3	143	24	patients	patient	NOUN
njb-3	143	25	on	on	ADP
njb-3	143	26	second	second	ADJ
njb-3	143	27	-	-	PUNCT
njb-3	143	28	line	line	NOUN
njb-3	143	29	antiretroviral	antiretroviral	ADJ
njb-3	143	30	therapy	therapy	NOUN
njb-3	143	31	at	at	ADP
njb-3	143	32	two	two	NUM
njb-3	143	33	hospitals	hospital	NOUN
njb-3	143	34	in	in	ADP
njb-3	143	35	western	western	ADJ
njb-3	143	36	oromia	oromia	NOUN
njb-3	143	37	,	,	PUNCT
njb-3	143	38	ethiopia	ethiopia	PROPN
njb-3	143	39	.	.	PUNCT
njb-3	144	1	plos	plos	PROPN
njb-3	144	2	one	one	PROPN
njb-3	144	3	.	.	PUNCT
njb-3	144	4	2019;14(12):e0225691	2019;14(12):e0225691	NUM
njb-3	144	5	.	.	PUNCT
njb-3	145	1	15	15	NUM
njb-3	145	2	.	.	X
njb-3	145	3	government	government	NOUN
njb-3	145	4	of	of	ADP
njb-3	145	5	nepal	nepal	PROPN
njb-3	145	6	mohap	mohap	PROPN
njb-3	145	7	.	.	PUNCT
njb-3	146	1	national	national	PROPN
njb-3	146	2	hiv	hiv	PROPN
njb-3	146	3	strategic	strategic	ADJ
njb-3	146	4	plan	plan	NOUN
njb-3	146	5	20162021	20162021	NUM
njb-3	146	6	.	.	PUNCT
njb-3	147	1	in	in	ADP
njb-3	147	2	:	:	PUNCT
njb-3	147	3	control	control	PROPN
njb-3	147	4	ncfaas	ncfaas	PROPN
njb-3	147	5	,	,	PUNCT
njb-3	147	6	editor	editor	NOUN
njb-3	147	7	.	.	PUNCT
njb-3	148	1	nepal2017	nepal2017	PROPN
njb-3	148	2	.	.	PUNCT
njb-3	149	1	sero	sero	NOUN
njb-3	149	2	-	-	PUNCT
njb-3	149	3	prevalance	prevalance	NOUN
njb-3	149	4	of	of	ADP
njb-3	149	5	cryptococcal	cryptococcal	ADJ
njb-3	149	6	antigenemia	antigenemia	NOUN
njb-3	149	7	in	in	ADP
njb-3	149	8	hiv	hiv	PROPN
njb-3	149	9	positive	positive	ADJ
njb-3	149	10	individual	individual	NOUN
njb-3	149	11	having	have	VERB
njb-3	149	12	cd4	cd4	PROPN
njb-3	149	13	counts	count	VERB
njb-3	149	14	<	<	X
njb-3	149	15	100	100	NUM
njb-3	149	16	cells	cell	NOUN
njb-3	149	17	/	/	SYM
njb-3	149	18	mm3	mm3	PROPN
njb-3	149	19	abstract	abstract	ADJ
njb-3	149	20	introduction	introduction	NOUN
njb-3	149	21	materials	material	NOUN
njb-3	149	22	and	and	CCONJ
njb-3	149	23	methods	method	NOUN
njb-3	149	24	results	result	VERB
njb-3	149	25	discussion	discussion	NOUN
njb-3	149	26	conclusion	conclusion	NOUN
njb-3	149	27	abbreviations	abbreviation	NOUN
njb-3	149	28	consent	consent	NOUN
njb-3	149	29	for	for	ADP
njb-3	149	30	publication	publication	NOUN
njb-3	149	31	competing	compete	VERB
njb-3	149	32	interests	interest	NOUN
njb-3	149	33	author	author	NOUN
njb-3	149	34	’s	’s	PART
njb-3	149	35	contributions	contribution	NOUN
njb-3	149	36	acknowledgment	acknowledgment	VERB
njb-3	149	37	references	reference	NOUN